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Sporadic Creutzfeldt-Jakob disease (sCJD) is an invariably fatal spongiform encephalopathy that
has a worldwide incidence of approximately 1/1, 000000 per year. Prospective surveillance has
been in place in the UK since 1990, coordinated by the National CJD Surveillance Unit (NCJDSU).
Accurate surveillance of CJD is important not only in detecting changes in patterns of disease and
predicting trends but also in instituting protective public health measures.
Aims of the study
To define circumstances where making a clinical diagnosis of sCJD is potentially problematic. To
explore ways of improving diagnostic accuracy and enhancing surveillance in these settings.
Methodology
Clinically "atypical" cases of sCJD were defined according to specific criteria (young, long
duration, certain focal features at onset) and identified by retrospective case-file review of all 485
pathologically-proven cases (1990-2002). Comparisons were made with a consecutively selected
"Core group" of "typical" sCJD (n=133). Cases identified only at autopsy, cases finally classified
as "Possible sCJD" (according to internationally agreed criteria) and initially suspect but
pathologically proven non-cases were also identified and analysed.
Results and conclusions
Twenty four per cent of all pathologicallly confirmed sCJD cases were "atypical". For each
"atypical" subgroup, relatively distinct phenotypic characteristics were identified when
compared with the Core group. Long duration cases were associated with early depression and
personality change, more psychiatric features and infrequent cerebellar or extrapyramidal
features. Young cases had less ataxia at onset and more psychiatric symptoms and involuntary
movements. Cases presenting with predominantly cerebellar features were associated with a
higher prevalence of visual disturbance and sensory symptoms and a longer illness duration.
Those with a pure visual onset had a shorter duration with less cerebellar or extrapyramidal
features. Amongst "atypical" cases (with the exception of pure visual onset cases) the
electroencephalogram was diagnostically less sensitive and where positive was associated with
short disease duration and increased age at onset. Visual onset cases were associated with
genotype MM at codon 129 of the prion protein gene. Nineteen per cent of sCJD cases were
referred after autopsy, of these about one third were not diagnosed whilst alive. Alzheimer's
disease (AD) was the most likely alternative diagnosis in pathologically proven non-cases except
when disease duration was less than six months, where paraneoplastic/neoplastic disease was
commonest. Diagnostic accuracy is likely to improve with a greater understanding of the range of
disease presentation, evolution and differential diagnoses along with the targeted use of
diagnostic tests. The referral of unusual cases should be encouraged. In view of the declining
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The primary aims of this study have been to identify the circumstances in which
making a clinical diagnosis of sporadic CJD is potentially problematic within the
United Kingdom and to explore ways of improving diagnostic accuracy and
enhancing surveillance in these settings.
The main objectives of the study were as follows:
To identify cases of sporadic CJD that were clinically atypical.
To describe in detail the phenotype of atypical cases and assess if particular clinical
features are likely to make diagnosis difficult.
To identify cases of sCJD that were not notified to the National CJD Surveillance Unit
(NCJDSU) in life and to explore possible reasons for this.
To describe the clinical features and methods of assessing cases of Possible CJD*
where the diagnosis remains uncertain. In doing this to discuss ways of improving
diagnostic certainty in this group.
To review the alternative diagnoses in pathologically proven non-cases who were
suspected of having CJD in life and to examine the clinical features in this group.
To assess the reasons why CJD was suspected in non-cases and to identify factors
that may help to distinguish CJD from other diseases.
*
Defined as Possible according to internationally agreed diagnostic criteria. When referring to Possible or
Probable cases according to the case definitions in the diagnostic criteria a capital "P" is used.
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Transmissible Spongiform Encephalopathies (TSEs)
The infectious agent
Transmissible Spongiform Encephalopathies (TSEs) are a unique group of
diseases in that they are thought to be caused by an infectious agent devoid of
nucleic acid known as the Prion. TSEs manifest in man either as sporadic, genetic
or iatrogenic diseases and are known to be transmissible (as first demonstrated in
the chimpanzee in 19681). Although the clinical disease spectrum may (initially at
least) be wide, all are characterized by progressive and fatal neurodegeneration.
Pathologically there is astrocytic gliosis, spongiform change and varying degrees
of cerebral atrophy 2. The presence of abnormal Prion protein plaques in the
brain are considered unequivocally diagnostic3.
The mysterious nature of the infectious agent has been the focus of much debate.
Previous theories speculated that the transmissible, disease-producing agent
could be a "slow virus" 4;5 (similar to that seen in subacute sclerosing
panencephalitis for example). Against this theory however is the lack of an
inflammatory response and the failure to isolate any virus. Also, the agent has
demonstrated extreme resistance to processes that would normally cause virus
inactivation (e.g. ultra violet and ionizing radiation) leading to the concept (first
defined in 1982)6 of a Prion. A normal cellular membrane prion protein exists
(denoted as PrP*7) whose exact function is poorly defined (turning off PrP0 in
mice appears to have no overt deleterious effect). There may, however, be a role
for PrP0 in resisting oxidative stress via copper/zinc superoxide dismutase7. The
pathogenic effect of TSEs involves the transformation of this normal, innocent
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form of prion protein into the abnormal and destructive PrP^ (where Sc denotes
scrapie). The polypeptide chains of PrPc and PrPSc are identical in composition
but differ in their three-dimensional, folded structures. PrPSc contains less alpha
helix and more beta pleated sheet than PrPC8. Once produced the PrF** stimulates
the conversion of more PrPc to PrPSc, setting in motion a chain reaction resulting
in the accumulation of the disease-producing isoform.
Disease in humans
TSEs are rare. They attract particular focus not only because of their
transmissibility and the inherently unusual nature of the infectious agent but
also because of the devastating nature of the resulting disease. A heightened
interest in this group of diseases has arisen in the United Kingdom following an
epidemic of a TSE in cattle in the 1980s (Bovine Spongiform Encephalopathy)
and its subsequent likely transmission to the human population in the form of
Variant CJD. Other TSEs known to affect humans and animals are detailed in
Table 1.1.
Sporadic CJD.
Sporadic CJD (sCJD) is the most common human TSE and exists worldwide (or
at least where surveillance systems are in place9). Historically, the first reports of
a sCJD-like illness were made by two German neurologists in the 1920s (Hans
Creutzfeldt10 and Alfons Jakob11) although some of the cases they described
would be considered highly unusual for the disease as it is recognized today.
sCJD has an incidence of approximately 1 case per 1 million of the population
per year (this rises to an incidence of 5 cases per 1 million per year for persons
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aged 50-64 years). The peak onset is in the sixth decade 12~14. A female
preponderance has been documented in some studies15 but not consistently16'17.
This is postulated to reflect the fact that sQD is predominantly a disease of older
age groups and life expectancy is longer in females (meaning that population
demographics may affect the gender distribution). The cause is unknown and
there has been no demonstrable link with the animal TSE scrapie or any
convincing, repeatable associations with environmental risk factors. It has been
hypothesized that the disease is first triggered by a somatic mutation in PrP,
leading to the alteration of PrPc by the mutant PrP^. The clinical features are of a
rapidly progressive dementia with approximately 65% of cases dying within six
months18.
Variant CJD.
Between November 1995 and March 1996 the National CJD Surveillance Unit in
the United Kingdom identified ten young people with CJD. These cases raised
specific concerns not only because of their age (cases in young people, including
teenagers, had been observed before albeit extremely rarely 19 22 ) but also because
of distinct clinical and neuropathological characteristics. Early psychiatric
features were noted to be prominent and some patients complained of striking
sensory symptoms. The widespread florid plaques, observed microscopically in
the brain tissue of all the cases, were unlike the findings reported in other CJD.
The report of these findings, entitled "A new variant of CJD in the UK" was
published in 199623.
Considerable evidence exists that vCJD is a consequence of human infection with the
BSE agent most probably through ingestion of infected beef. There is a spatial and
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temporal association between BSE and vCJD 24;25. Retrospective studies examining
autopsy findings and death certificates have not revealed any cases of previously
undiagnosed vCJD26;27. The vast majority of vCJD has been observed in the UK and
despite enhanced surveillance in other European countries and the United States,
Canada and Australia similar patterns of disease have not emerged.
In addition, studies of mice expressing the bovine PrP transgene have revealed the
same incubation times, neuropathological features and patterns of PrP^ deposition
regardless of whether the inoculate originated from the brains of BSE cattle or from
humans with vCJD3. Transmission of BSE to primates results in a similar
neuropathological appearance to that seen in humans with vCJD28;29. A distinct prion
protein structure has been observed in both vCJD and BSE30-31 and PrP strain typing
experiments indicate that vQD and BSE exhibit the same Prion strain (which differs
from that observed in sQD or scrapie)32;33.
The range of ages at onset in vCJD is 12-74 years with a median of 26 years34.
Clinical features in vCJD are relatively distinct and stereotyped with most
presenting with psychiatric features and/or a sensory disturbance3537. Common
early psychiatric features include dysphoria, withdrawal, anxiety, insomnia and
loss of interest37. Neurological features may be present at onset and are seen in
over 75% by six months 37. The disease progresses to a dementia with increasing
physical debility and a median duration of illness of 14 months (range 6-39
months)34
All tested vCJD cases to date have been homozygous for methionine at codon 129 of
the prion protein gene34. Diagnostically, an abnormal area of high signal observed in
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the posterior thalamus on magnetic resonance imaging (the "pulvinar sign") has
proved an important, sensitive and non-invasivemarker for vCJD38.
Recent reports indicate that the incidence of vCJD may be in decline39 although
concerns still exist as to the possibility of secondary transmission (for example
through blood or blood products)40 and the possibility of codon 129 heterozygous
cases presenting in novel ways.
Genetic CJD.
Genetic CJD (gCJD) is responsible for about 10 to 15 per cent of all CJD 14. Familial
cases of CJD have been reported since 1930 and the transmissibility of gCJD to non-
human primates was first reported in 1973 18. In gCJD there is an underlying
mutation of the PRNP gene leading to the production of a PrP protein molecule
thought to be predisposed to developing into PrPSc. The mutation is inherited in an
autosomal dominant manner. Differentmutations are associated with different
phenotypes and include Gerstmann-Straussler-Scheinker syndrome (GSS) and Fatal
Familial Insomnia (FFI). In some cases the clinical phenotype is similar to sCJD.
Gerstmann-Straussler-Scheinker syndrome (GSS) typically manifests as a progressive
cerebellar ataxia and is associated with mutations at codon 102 (the most common),
212, 217, 117,198,145 and 105 of the PRNP gene u. Dementia commonly ensues (but
is often delayed) and associated features include a spastic paraparesis and
extrapyramidal signs18. The duration of illness may be much longer than that seen in
sCJD, averaging five years 41.
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Fatal Familial Insomnia (FFI) was first described in 1986 42 and subsequently has been
described in over 20 families43. Sleep disturbance is an early sign (progressing until
normal sleep is not possible) along with autonomic dysfunction including increased
lacrimation, sweating, raised body temperature and impotence in males 42. Cognitive
impairment usually develops relatively late in the illness44. Pathologically there is
marked thalamic gliosis with little or no spongiform change 45. FFI is associated with
a mutation at codon 178 of the PRNP gene in the presence of a polymorphism coding
for methionine on the affected allele46. Onset is usually in the fifth decade with
illness durations averaging 13-15 months (range 6-42 months) 4749. There are some
reports of sCJD with a clinical phenotype similar to that seen in FFI (termed sporadic
familial insomnia)50.
Iatrogenic CJD.
Iatrogenic CJD (iCJD) is the accidental transmission of CJD during medical or
surgical treatment. Cases of iCJD have been reported following neurosurgery
51;52including the use of EEG depth electrodes53, corneal grafting54, and human dura
mater grafts55'56. Iatrogenic CJD has also been reported after the use of cadaveric
human growth hormone (hGH) 57 and human pituitary gonadotrophin. The first
report of iatrogenic CJD was in 1974 and concerned a recipient of a human cadaveric-
derived corneal transplant54. This was followed in 1977 by transmission from EEG
depth electrodes 53 and the first cases of CJD in human growth hormone recipients
were recognized in 198558 (over 140 have subsequently occurred). Most of the cases
of iatrogenic CJD relate to the use of human cadaveric-derived growth hormone or
dura mater grafts25.
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The clinical features in iCJD depend on the route of infection. Peripherally acquired
hGH cases (occurring as a result of intramuscular injections of the infected material)
generally present with a progressive cerebellar syndrome, often with a delay in the
onset of a dementia59. Human dura mater cases and those occurring as a result of
other neurosurgical procedures, i.e. as a result of direct inoculation into the central
nervous system, tend to present with a rapidly progressive dementia similar to that
seen in sCJD12. In a few of these cases, however, a cerebellar syndrome has been
described60. There is an association with the incubation period and the route of
transmission, with central inoculation leading to a shorter incubation period than
peripheral inoculation14.
Kuru.
Kuru is a TSE, now virtually extinct, confined to the highland regions of Papua New
Guinea. The word "kuru" means "to shiver" or "to be afraid" in the local Fore dialect.
These symptoms along with cerebellar ataxia are the most striking clinical features of
the disease. The first report of a case was made in 1953 61 and the epidemic reached
its peak in 195662. More than 2600 people have died from the disease since it was first
reported 63. Intensive epidemiological studies concluded that the likely cause of the
disease was the practice of ritual cannibalism resulting in the serial passage of an
indigenous case of sporadic CJD 14;18 . Women and children were more frequently
affected than men and this reflected their practice of eating less desirable body parts
(which would include the highly infectious central nervous system). Symptoms were
observed in children as young as four years of age.
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Fatal Familial Insomnia Humans
Kuru Humans (Fore people in Papua New
Guinea)
Scrapie Sheep
Bovine spongiform encephalopathy Cattle
Transmissible mink encephalopathy Mink
Chronic wasting disease Mule, deer, elk
Feline spongiform encephalopathy Cats
Exotic ungulate encephalopathy Greater kudu, nyala, oryx
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The importance of studying sCJD
Sporadic CJD remains the most common TSE. The significance of previous work into
sCJD was highlighted when vCJD was identified. Without previous surveillance
work highlighting the clinical phenotype, epidemiological characteristics and
pathological features of sCJD it would have been difficult to identify the unusual
nature of variant CJD.
As a result of public health concern and interest from the media, attention has tended
to focus on vCJD since its emergence in 1996. Sporadic CJD, however, presents
several unique opportunities for further study. It is widely acknowledged that the
clinical spectrum of disease in sCJD may be diverse12;13;64;65, sometimes to the extent
that even those most experienced in its diagnosis fail to suspect it. This is not the case
in vCJD where the symptoms and signs are to date more uniform. The variation in
clinical phenotype seen in sCJD makes clinical diagnosis more challenging. For
diagnostic accuracy to be maintained a broad understanding of disease
manifestations is required. A comprehensive description of the disease phenotype as
part of this study will aid pattern recognition and the identification of unusual cases
in the future.
Diagnosing all types of CJD accurately is important not only for appropriate
counselling, provision of care andmonitoring of trends but also because of concerns
regarding onward transmission of the infective agent. Contact with potentially
infected instruments or tissue without adequate precautions is particulary pertinent
in unusual cases of sCJD when the clinical phenotype is not recognised. The study of
the phenotypic diversity observed in sCJD may provide further insights into the
pathogenesis of prion diseases.
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Sporadic CJD differs from vCJD in the genotype expressed at codon 129 of the prion
protein gene. In vCJD all clinically evident cases tested to date have been
homozygous for methionine (MM) at codon 129. In sCJD, in addition to the MM
genotype, valine homozygotes and methionine/valine heterozygotes manifest
disease. This genetic variation provides an opportunity to examine the impact of
PRNP genotype on clinical presentation. This could be useful in aiding the
identification of vQD in non-MM cases in the future.
The emergence of vCJD has shown the importance of seeking a complete
understanding of transmission, geographical distribution, risk factors, clinical
features and diagnosis even in rare diseases. This study seeks to refocus attention on
the clinical features and diagnosis of sCJD in order to add to the understanding of
disease manifestations and potential inaccuracies in diagnosis.
Clinical features in sCJD
It should be emphasized that many studies identifying clinical features in sCJD were
retrospective and involved examining clinical notes from patients who may or may
not have been assessed by a neurologist. This accounts for some variation in the
quality of data collected in previous studies and indeed is likely to lead to
inaccuracies in reporting. Prospective collection of clinical data by surveillance
neurologists is likely to lead to more uniform and accurate documentation of clinical
features within a population. This thesis is concerned with clinical data collected
largely from clinical examination by a surveillance neurologist, which was collected
prospectively using standardized proformas.
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Typical sCJD
In order to appreciate the clinical diversity seen in sCJD it is first necessary to define
what constitutes a typical case. The typical phenotype of sCJD is one of a rapidly
progressive dementia associated with myoclonus and a range of neurological deficits
66. It has been summarized as:
Progressive dementia....together with one or more symptoms referable to
the pyramidal, extrapyramidal, visual or cerebellar systems. At an
advanced stage of illness, myoclonus...and a suggestively abnormal EEG
are observed. Death occurs two to five months after the onset of illness as
a result of cachexia, intercurrent infection and cardiopulmonary collapse.
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When making the diagnosis a triad of classical features may be noted 52;68, consisting
of a rapidly progressive dementia accompanied by myoclonus and a characteristic
EEG 14. The mean duration of illness is four months13 and around 65% of cases have a
total illness duration of less than six months 18. The majority of cases are
characterized by a dementia "rapidly leading to a helpless condition and an early
death"
Clinical features may vary considerably from individual to individual12 and
oversimplifying the clinical picture may be misleading. Atypical features in sCJD are
well recognized as Brown et al concluded in a study of 300 experimentally
transmitted cases:
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Sporadic CJD cases show a wide spectrum of clinical features. There are
extremes in a continuum of clinical profiles that centre on the more
"typical" subacute progression of mental deterioration; cerebellar, visual,
pyramidal and extrapyramidal signs; involuntary movements and a
periodic EEG. CJD is one disease with a single pathogenesis, expressed in
kaleidoscope variety 13.
This study was important as it highlighted phenotypic variations in sCJD. It was
however inaccurate in describing CJD as "one disease" when the genetic and
iatrogenic forms had already been well-described. Since then, the emergence of vCJD
has highlighted that CJD is clearly not a uniform entity and cannot be regarded as a
single disease. They may pose problems in identification of cases. An understanding
of the breadth of the disease phenotype is important in ensuring accuracy in any
surveillance system.
Presenting features in sCJD
The most commonly observed presenting features in sCJD are in order of frequency:
dementia, ataxia or visual disturbance69 (see Table 1.3). A "prodrome" of non-specific
symptoms such as weight loss, malaise or personality change has been described by
Will and Matthews 64 and noted elsewhere in about one quarter of patients 13. These
prodromal symptoms may be given extra significance in retrospect and it is difficult
to be sure of their significance. In one series prodromal symptoms were as common
in corresponding hospital controls n.
Relatively uncommon, but well characterised presentations include the Brownell-
Oppenheimer variant70 which is associated with cerebellar features at onset and the
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Heidenhain variant71:72 (where disease presentation consists of predominantly visual
symptoms). An acute presentation, initially mistaken for a stroke, has been described
and is thought to occur in up to six per cent 73This may reflect early inaccuracies in
history taking rather than a truly abrupt "stroke-like" onset. Often the progressive
nature of symptoms is evident from the outset clinical details are elucidated
carefully. Sleep disturbance and a phenotype indistinguishable from Fatal Familial
Insomnia has been described sporadically where no mutation in the prion protein
gene was found 50. There are case reports of presentations with cortical deafness 74;75,
pruritus 76, progressive and initially isolated aphasia 77:78 a myoclonic alien hand 79
and complex partial status epilepticus80.
Although the presenting neurological features may be focal, in the majority these are
soon engulfed by a rapidly progressive global encephalopathy with an increasing
physical dependence, akinetic mutism, dysphagia, periodic respiration and death
commonly from bronchopneumonia.
The "Heidenhain variant" of sCJD
The "Fleidenhain variant" of sporadic CJD is distinguished from the more typical
descriptions of the disease by a profound involvement of visual function at the
disease onset. The three original cases were described by a German neurologist,
Heidenhain, in 192971. All had pathological changes of a spongiform encephalopathy.
In two of the cases there were early, prominent visual symptoms progressing to
cortical blindness and both of these were associated with severe pathological change
in the occipital lobes of the brain. The third case had early sensory symptoms
associated with athetosis of the left upper limb and no associated visual disturbance.
In 1954 Meyer et al72 described the case of a 38 year old man who "became forgetful,
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experienced difficulty in concentrating...became irritable, suffered from headaches
and his vision began to fail". A right homonymous hemianopia was detected on
examination and he died six months after the onset of symptoms. Again pathological
changes were most severe in the occipital lobes and they proposed the term
"Heidenhain's syndrome".
Visual symptoms are relatively common in sporadic CJD81 (see Table 1.3) and there
is some debate over what constitutes a useful definition of a Heidenhain case. The
largest series looking at the incidence and nature of this clinical subtype found that of
169 patients with neuropathologically confirmed sCJD, 34 (20 per cent) met the
definition of:
predominant visual impairments at the onset of disease, consisting of
deterioration of vision, blurred vision or visual field restriction, vision loss
up to cortical blindness, disturbed perception of colours or structures,
optical hallucinations and optical agnosia82.
Other sources have estimated an incidence of ten per cent if the definition of
"presentation with prominent visual disturbance" is applied 81. These patients would
often present first to an ophthalmologist and in recent years have become
increasingly recognized within this specialty 81;83.Cognition may be preserved until
some weeks into the illness84 although deterioration is often rapid once a dementia is
evident.
Those working in the field of CJD surveillance recognize that a distinct group of
patients exist in whom visual symptoms are present in isolation at onset (rather than
simply prominent in the context of other symptoms). The above definitions do not
distinguish between those who have visual symptoms along with other features at
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presentation and those who have visual symptoms in isolation and in this respect the
term has been used carelessly. It is the cases who present with isolated visual
symptoms that may pose the greatest problems in terms of early, accurate diagnosis
and potentially needless eye surgery (for example cataract extraction).
The Brownell-Oppenheimer form ofsCJD
About forty years after the original descriptions by Creutzfeldt and Jakob several
case reports were published highlighting a fatal ataxia-dementia condition
referred to at the time as "an ataxic form of subacute presenile
polyencephalopathy (QD)" 70. The condition, subsequently named after the two
authors of the original report, consisted largely of a rapidly progressive ataxia
(preceded by a sensory disturbance in five out of ten patients) followed some weeks
later by a progressive dementia. It was considered to be a distinct clinical entity
with pathological changes similar to those seen in the "larger group of
Creutzfeldt Jakob Disease"70. Involuntary movements (often myoclonus) were
observed in the majority and the mean disease duration in these ten cases was 7.5
months (range two and a half to 13 months). No familial associations were
found.
The Brownell-Oppenheimer form of CJD may cause diagnostic uncertainty largely
due to the isolated cerebellar features at onset in the absence of an early dementia. A
progressive and isolated cerebellar ataxia raises a number of possible diagnoses and
CJD is understandably not the foremost. Estimates of the incidence of this virtually
isolated cerebellar onset amongst sCJD as a whole are not clearly defined but are
likely to be significantly less than one third 13. Ataxia at onset in sCJD is common but
usually occurs with a coexistent rapidly progressive dementia. These circumstances
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would not represent a Brownell-Oppenheimer case as it is the virtually isolated
cerebellar features at onset that are characteristic of this form of sCJD. The Brownell-
Oppenheimer form of sCJD may be particularly distressing because patients
maintain insight into their condition for some weeks or months into their illness.
Many, however, soon come to resemble the more typical phenotype of sCJD once
dementia is present as the rapidity of global decline often mirrors that of sCJD as a
whole.
An important differential diagnosis to consider in this group is that of genetic CJD
which may also present with a pure cerebellar syndrome 85. In these circumstances it
may be referred to as Gerstmann-Straussler-Scheinker syndrome (GSS)86.
Early and dominant cerebellar features, in the absence of familial disease, have been
associated with valine homozygosity at 129 of the prion protein gene87.
Neurological signs in sCJD
Myoclonus is an important clinical sign. During the course of the illness it emerges in
approximately 80% of patients 12;13;88 (Table 1.4) although it is rare at presentation. It
is most frequently observed in the limbs and usually shows some asymmetry. In
sCJD myoclonus is commonly spontaneous but may also be observed in response to
sudden noise, touch or light and in these circumstances an excessive startle reaction
is also often seen89. Myoclonus may be seen in as many as 20% of patients with
Alzheimer's disease90. It is also recognized in those with dementia with Lewy bodies,
leading to some diagnostic confusion 91.
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Pyramidal signs are commonly observed (Table 1.4). These tend to consist of
hyperreflexia and extensor plantar responses but a definite spastic paresis is unusual.
A gegenhalten, paratonic form of rigidity is frequently described and in some studies
is considered as a pyramidal sign M, although often it is regarded separately88.
Extrapyramidal features, most commonly consisting of lead-pipe rigidity, have been
documented with varying frequency in different series (see Table 1.4). This variation
is likely to reflect the different classifications of rigidity 64'69'88.
Cerebellar features have been found in between 61%69 to 86% of patients 92and
usually consist of an ataxic gait, vertigo and nystagmus. Truncal and limb ataxia,
tremors and dysarthria occur less frequently 13.
Word-finding difficulties may be an early feature with loss of speech occurring
relatively early on in the illness at an average of 13 weeks after symptom onset93
Mutism is recorded in up to 100% 64. Primitive reflexes are present in the majority of
cases studied in detail but are not documented in all cases where information was
collected retrospectively.
Visual disturbance is frequently encountered and thought to progress to cortical
blindness in the majority of cases 12. Abnormal eye movements have been described
in the literature but are uncommon. Most frequently reported is a paresis of
conjugate upward gaze (Parinaud's syndrome) seen in five per cent of patients 13.
Individual cranial nerve palsies other than sixth nerve palsies are rarely seen.
Documented visual or oculomotor symptoms/signs are listed in Table 1.2.
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Visual inattention or neglect69










Sensory symptoms may be present in up to 11%69 and have been described as
parasthaesias, itching or pain 16. Sensory features are generally a more striking
feature in vCJD111.
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Seizures are very unusual at presentation and seen in eight69 to 19% 13 at some stage
in the disease. Severe myoclonusmay be mistaken for epilepsy and this reflects an
intrinsic problem with some of the data used in studies. Reliance is often placed on
information gained from the case notes and to an inexperienced clinician myoclonus
may be misjudged as representing a seizure. Lower motor neuron signs are relatively
rare, reported in approximately ten per cent69 Although peripheral nerve
involvement has been documented using electrophysiological techniques 112 this was
largely sub-clinical and clinically-evident peripheral neuropathies are rare113. Many
historical "amyotrophic sCJD" cases were, in hindsight, likely to represent motor
neuron disease with dementia rather than a TSE. Transmission studies uniformly
failed to pass on any infection in these cases114 calling into question the diagnosis of
TSE. A recent review of amyotrophy in prion disease looked at case reports dating
from 1968 in pathologically proven (and transmissible) cases. Amyotrophy was
defined as "clinically evident fasciculations with or without electromyographic
evidence of denervation". Clearly this leaves room for error as fasciculations may be
regarded as a normal finding in some adults without associated muscle wasting or
weakness. Evidence of amyotrophy (according to this definition) was found as an
occasionally prominent feature. However, the authors of the study expressed the
need for further clarification of both the definition of amyotrophy and its incidence
along with neuropathological examination of the spinal cord115. Amyotrophic CJD
remains a poorly-defined concept.
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Patients with an unusual age at onset or long illness duration
Two groups of patients with sQD stand out from the typical descriptions of the
disease because of their young age or long disease duration. These two groups will
form part of an overview on atypical cases conducted in this work.
There is a consistently noted association between a relatively young age at onset
and a longer disease duration 1J;13;65, suggesting overlap between these two
groups. Reasons for this may include an increased likelihood of identifying
subtle early symptoms in the young and a propensity to artificially feed and
therefore sustain young patients. In addition, the inclusion of unidentified
familial cases which are associated with a younger age at onset, the absence of
other co-morbidity which may hasten death and a slower disease progression per
se in the young may influence duration. The longer duration may also reflect
different mechanisms of pathogenesis in the young which are not fully
understood.
Clinical features of young cases
The mean age of onset of sCJD is about 65 years 12;13;116;n7. The youngest known case
of sCJD occurred in a 14 year old 19 but cases under the age of 50 are rare at between
three118 and 12% 13of total sCJD cases. In those under 50 years of age in France,
Germany, Italy, the Netherlands and the UK the incidence rate of sQD between 1993
and 1995 was calculated at 0.27 per million u9. The annual incidence in persons aged
less than 40 and 30 is approximately 50 and five per billion respectively 9;119.
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One of the concerns when the NCJDSU identified the first vCJD cases was that
previous diagnoses of sCJD in young people may have actually been vCJD. A review
of the pathology in young cases known to the NCJDSU failed to demonstrate that
this was the case (Professor James Ironside, personal communication)
Long duration cases
The median duration of illness in sCJD is approximately 4.5 months and
approxmately 65% die within six months18. Ten to 14 per cent of patients with sCJD
live for longer than one year and approximately five per cent live for longer than two
years 13;18. Exceptionally, illness durations of greater than five years have been
recorded, although in some of these the question of familial CJD has not been
adequately addressed with genetic testing. As the diagnosis in sCJD often rests on
the rapid clinical evolution of neurological abnormalities these long duration cases
may pose particular problems in reaching an accurate diagnosis in life. Indeed,
current internationally agreed diagnostic criteria for sCJD (see Table 1.11) do not
allow any case with a disease duration of greater than two years to be classed even as
a Possible case*.
It may be impossible to distinguish long duration cases clinically from Alzheimer's
disease or other chronic, progressive dementias 120 and the diagnosis may only be
recognized upon autopsy. A rare scenario that needs to be borne in mind is that of
the coexistence of Alzheimer's disease with CJD, which has been highlighted in
several case reports 121123.
*
Unless an EEG is recorded which shows a typical appearance for sCJD.
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Difficulties may exist in deciding whether some symptoms are clinically relevant and
erroneously long durations may be noted. For example, amongst those reported with
disease durations of greater than ten years some authors have included a slowly
progressive anorexia nervosa syndrome65 and a progressive gait disturbance over 16
years 64 which seem more likely to represent unrelated conditions rather than the
onset of CJD.
The largest series of long duration cases 65 identified 33 (nine per cent) of 357
pathologically-proven CJD cases with a duration of two years or more. It is
important to note however that 30% of these long duration cases were of genetic CJD.
Despite this, an association between younger age at onset illness duration was found
which appeared to act independent of genetic factors and has been observed
elsewhere945. Brown et al concluded from this study that the clinical course in long
duration cases of sCJD can vary in three ways:
1. An initial, long and slowly progressive first stage of illness followed by
a shorter, rapid terminal phase
2. A fairly steadily progressive clinical course with a stepwise addition of
increasingly serious neurological abnormalities
3. An initial rapid deterioration followed by a nearly stable or very
slowly progressive terminal phase ofmute stupor and complete
physical dependence.
These observations were echoed in the work of Will and Matthews who summarized
the clinical features of cases from 1970-1979 with a duration of illness of greater than
16 months (which they termed an "intermediate form" of CJD)64. As genetic analysis
was not performed in these cases it is unknown how many had a disease associated
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PRNP mutation. The lack of any mutation analysis questions the credibility of
thinking of such cases as "sporadic". It is accepted that genetic disease is less likely in
the absence of a family history, but by no means excluded.
In Japan the more intensive approach to terminal care in sCJD with advanced
supportive measures may partially explain the mean duration of illness of 16.6
months 124. It does not however account for the observation that the average duration
between onset and akinetic mutism was prolonged to 10.5 months, on average, in
these cases.
It has been demonstrated that those patients exhibiting periodic sharp wave
complexes on the EEG tend to have shortened illness durations when compared with
those cases of sCJD without these EEG features 15;125. This may overlap with the
observations linking the genotype at codon 129 of the PrP gene with a characteristic
EEG appearance (seen predominantly in methionine homozygotes) and disease
duration S7. By studying long duration cases from the cohort of pathologically proven
sCJD cases collected by the surveillance system over a 12 year period this study seeks
to test out both the clinical and genetic associations outlined above.
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n=124 n= 137 N=230 n=232 n=144 n=122
% pathologically
confirmed
100" 77a 100a >95 84 58
Memory loss 48
Dementia 29 21 31 61 50


















Headache 10 3 7 11
Sensory 2 4 5 6 3 4




1 5 <1 4 1 2
a These studies include between four and ten per cent of familial cases
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Table 1.4: Symptoms and signs throughout the course of the illness in six clinical



































% PM proven 100 77a 1001 >95 84 58 51
Dementia 94 100 96 100 96








































Pyramidal signs 44 79 (inc
rigidity)











Seizures 9 9 8 19 13 28 12
a These studies include between four and ten per cent familial cases
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The role of diagnostic tests in sCJD
Although neuropathological examination of brain tissue remains the "gold standard"
for diagnosis in CJD, recent advances in the utilization of specific diagnostic tests
have greatly enhanced clinical diagnostic certainty. Less is known, however, about
the value of these tests in specific clinical contexts (e.g. with clinically unusual cases).
The degree to which investigations are employed by the clinicians directly involved
with patient care is also uncertain. This study will examine these issues.
Cerebral magnetic resonance imaging
Several features on cerebral MRI have been recognized in sCJD but they are not
considered specific enough to be included in the internationally recognized
diagnostic criteria (Table 1.11). The MRI scan may be normal in sCJD105;126.
Abnormalities described include atrophy, basal ganglia and thalamic changes and
cortical hyperintensity.
Atrophy on MRI in sCJD.
Brain atrophy is a non-specific finding and therefore not useful in differentiating
sCJD from other neurodegenerative diseases. It has been described in about 30% of
cases in two separate studies126'127. Patterns of atrophy may be focal or generalized128
and as the disease progresses the development of increasingly severe atrophy has
been observed 127;129. Generally the presence of cortical atrophy is a late feature and
correlates with the duration of disease 105;129.
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High signal in the basal ganglia in sCJD.
The first series that identified abnormal areas of high signal in the caudate head and
putamen on MRI found 79% of 29 patients displayed these abnormalities on T2 and
proton density sequences 105. A larger German study observed basal ganglia high
signal changes in 67% 127. These basal ganglia changes can be difficult to interpret in
people below the age of 40 years because of intrinsic intermediate signal intensity of
the putamen and globus pallidus seen in normal individuals 130. Basal ganglia
changes have been observed as early as three weeks after onset of symptoms 131 and
have been recorded before typical EEG changes were evident132. Less frequently
hyperintensity is observed in the globus pallidus, thalamus and periaqueductal grey
matter 127
One of the difficulties with the MR abnormalities in the caudate head and putamen
are the fact that they can also be seen in other diseases. Similar appearances have
been described in hypoxic encephalopathy, carbon monoxide poisoning,
hypoglycaemia, haemolytic uraemic syndrome, encephalitis, mitochondrial
disorder's (e.g. Leigh's disease), Wilson's disease and Huntington's disease 133-134.
However, it is usually possible to differentiate between these disorders and sCJD
clinically and specificity for sCJD may be as high as 93% amongst those thought
clinically to have sCJD105.
Cortical hyperintensity in sCJD.
Cortical high signal is reported less frequently than the changes observed in the basal
ganglia. The best estimate of prevalence comes from the series of 29 patients
mentioned above, where 14% displayed signal change in the cortex 105. High signal in
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the cortex has been reported soon after disease onset (before high signal in the basal
ganglia was observed) andmay therefore be regarded as a relatively early sign98;135137
. Ribbon-like hyperintensities in the cerebral cortex have emerged as a potential aid
to diagnosis early in the condition when diffusion weighted imaging is employed m.
These abnormalities may be present when both the EEG and CSF are not diagnostic
139-141
The Electroencephalogram (EEG)
The characteristic EEG pattern seen in sQD is that of periodic sharp wave
complexes (PSWCs) seen throughout the recording 12;142;143 as shown in Figure 1.1.
Studies report a prevalence of this abnormality of between 55 per cent and 85 per
cent13;64;144 of patients with sCJD. This figure is likely to be in decline, however, as
serial EEG recordings may no longer be frequently employed since the advent of
other diagnostic tests (such as CSF 14-3-3). A large, prospective, multi-centre study of
219 sCJD cases found a "typical" EEG had a sensitivity of 66% and a sensitivity of
74%145. One of the difficulties with all of the studies looking at the prevalence of a
typical EEG appearance is absence of or discordance in the definition of a "typical"
recording. Within the UK surveillance system a five-level EEG grading system is
employed (Appendix 2) and each EEG is reviewed by one of two NCJDSU doctors
blinded to the diagnosis. In many other centres reporting from local physicians is not
reviewed separately and it is unclear if EEG grading is standardised, potentially
leading to bias in any estimates of the prevalence of typical EEG recordings.
The appearance of PSWCs depends on the clinical stage of the illness, being more
often seen later in the disease 142n46;147. A typical recording is more commonly seen in
those with a MM1 genotype at codon 129 of the PRNP gene87. From a clinical
45
perspective it has been shown that a duration of illness of greater than one year or a
presentation with ataxia make the development of PSWCs less likely 65:69. The EEG
appearance is considered specific enough to be included in the internationally agreed
diagnostic criteria (Table 1.11). Other causes of a "sCJD-like" EEG may cause
confusion (Table 1.5) if not excluded.











Other condition reported to cause a similar picture but either reported to be "suggestive" only or not
reproduced include normal pressure hydrocephalus, cerebral lipidosis, holoprosencephaly, lymphoma,
hyperammonaemia, multiple myeloma, hypo and hypernatraemia, cerebral abscesses, amitriptylline
toxicity, metrizamide toxicity and Lewy body disease. (List reproduced from "A. new variant of
Creutzfeldt-Jakob disease in the United Kingdom" MD thesis by Martin Zeidler, with the written
permission of the author).
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Figure 1.1: A "positive" EEG in sCJD
CSF 14-3-3
14-3-3 is an abundant, acidic brain protein which, when detected in the cerebrospinal
fluid of individuals with a clinical picture consistent with CJD, has significant
diagnostic value158 160. The reported sensitivity of 14-3-3 ranges from 77 to 100 per
cent159;161;162 with specificities of between 87 and 100 per cent1591161. Central to the
accuracy of the test is the selection of the patient group because false positive results
are well documented in other conditions. These, however, are often clinically distinct
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from sCJD 162 165. Table 1.6 lists some of the other diagnoses found in cases referred to
the NCJDSU for CSF analysis only.
CSF 14-3-3 was recently incorporated as a diagnostic test in World Health
Organisation (WHO) and European Union (EU) criteria for sCJD166;167 (see Table 1.1).
This decision followed a large, multi-centre prospective study that found a positive
predictive value of 94% and a negative predictive value of 82% amongst clinically
Possible cases 145.
Table 1.6: Diagnoses in patients with positive CSF 14-3-3 referred to the NCJDSU
in 2003 for CSF analysis only
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Diagnosis (number of patients)
Unspecified psychiatric disorder (2)
Improved (1)
Demyelination (1)
Hyponatraemia and seizures (1)
Neuropathological examination not consistent with CJD (1)
Neuropathologically proven encephalitis (1)
Lewy Body Disease (1)
Hydrocephalus (1)
Vascular Disease (1)
Motor neurone disease (1)
Probable CNS inflammatory disorder (1)
Unspecific encephalopathy (1)
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The Differential diagnosis of sCJD
Approximately one half of patients referred to the NCJDSU have a final diagnosis
other than CJD or the diagnosis remains uncertain. Differentiating between CJD and
other neurodegenerative diseases accurately has implications for the patient, the
family, health care providers and potentially the wider community. Although in
many cases distinguishing clinically between sCJD and other diseases may not be
problematic, this study seeks to identify the cases that are difficult to diagnose
clinically and what features make diagnosis problematic. Table 1.7 outlines the most
common differential diagnoses of CJD found in three surveys.
Other neurodegenerative disorders and sCJD
Previous studies have demonstrated that the most common diagnosis in postmortem
confirmed non-cases is Alzheimer's disease64'92.There may be particular difficulty
distinguishing between sCJD and Alzheimer's disease with myoclonus, especially
when the Alzheimer's disease is of short duration92. To add to the diagnostic
confusion the typical EEG of sCJD has been described in Alzheimer's disease92;168.
One study compared the clinical features of 31 cases of pathologically-proven
Alzheimer's disease and Lewy body dementia (who in life were considered to have
sCJD) with a control group of 25 patients with sCJD. They found that dementia,
rigidity and myoclonus were common in all three groups and recommended that,
when faced with this triad, QD should be the first line diagnosis but that
Alzheimer's disease should be considered if the disease course is longer and Lewy
body dementia if parkinsonism or fluctuations in clinical state were present91.
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Although broadly useful, this work did not identify clear differences that could be
applicable in individual cases. This reflects the overlap between the disorders
sometimes seen. More should be done to encourage autopsy in unusual cases.
Genetic, iatrogenic and variant CJD as differential diagnoses of sCJD
The other main differential diagnoses of sCJD are other types of CJD. Genetic CJD
(gCJD) may present in a similar fashion, particularly when the disease is associated
with the E200k mutation in the prion protein gene 169 and genetic testing should be
offered routinely, even in the absence of a family history of CJD. The diagnosis of
probable iatrogenic CJD (iCJD) rests on the identification of exposure to the infective
agent coupled with clinical evidence of a TSE. In some cases the possibility of sCJD
cannot be excluded. The presence of prominent and early cerebellar features may
alert a clinician to iCJD as a potential diagnosis. Sporadic CJD can present in this
manner, however, as the previously described Brownell Oppenheimer form.
Some cases of sCJD may present with features more commonly associated with
vCJD. In 30 cases where vCJD was originally suspected sCJD was the diagnosis
proved at autopsy in nine170. The distinction between variant and sporadic CJD may
become more difficult in atypical longer duration cases or when the patient is young.
A recent case report of a 36 year old woman with sCJD who presented with
psychiatric features highlighted these difficulties171.
Case reports exist of a range of other conditions mistaken for sCJD. These are
summarised in Table 1.7 and Table 1.8.
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Table 1.7: The differential diagnosis of sCJD in three studies*
(numbers in brackets indicate cases with neuropathological data)






Alzheimer's disease 20(3) 28(5) 34 (13)
Cerebrovascular
disease











5 (1) 1(1) 3 (2)
























Other diagnoses found at autopsy include the following (found in single patients only):
leucodystrophy, fatal familial insomnia, congophilic angiopathy, lipoid histiocytosis, alcohol
induced atrophy, gliomatosis cerebri, hypoxic brain damage, astrocytoma.
a Cases certified as dying ofCJD in which the diagnosis was reclassified after review of clinical data or
pathology
b Cases referred as suspect CJD in which the diagnosis was reclassified after review of clinical data or
pathology
0 Cases referred as suspect CJD with neuropathologic confirmation of alternative diagnosis
Other diagnoses (where findings at autopsy are not specified) each for n=l in England and Wales
studies: Herpes simplex encephalitis, familial spinocerebellar degeneration, multiple cerebral
abscesses, stroke, carcinomatous meningitis, glioblastoma, post-anoxic encephalopathy, cerebral
metastases, hepatic encephalopathy, progressive supranuclear palsy.
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Table 1.8 Additional reports of conditions mistaken for CJD
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Gadea & Soriano, 1999"3
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Kida et al, 1988150
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Von Bose & Zaudgig, 1991174; Gordon et
al, 1995175
Foerstl et al, 1989176
Koponen et al, 1990177
Broussolle et al, 1989178; Casanova et al,
1996179; Finelli, 1992180; Kikyo &
Furukawa, 1999156; Masmoudi et al,
1996181; Primavera et al, 1989182; Smith &
Kocen183, 1988;







Bilateral Ammon's horn atrophy
Ceroid lipofuscinosis
Brown et al, 199413
Brown et al, 199413
Brown et al, 199413
Brown et al, 198669
Brown et al, 198669
Brown et al, 199413
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Disease surveillance
All of the data used in this study have been collected through a disease surveillance
system. An understanding of how this system has evolved along with an
appreciation of the basic principles of disease surveillance is essential to appraise the
quality and content of the data. Disease surveillance may be defined as:
"Ongoing scrutiny by methods that are practical, uniform and rapid. It
has the purpose of detecting changes in trends or distributions, in order to
initiate investigations or control measures" 183
To be effective, a surveillance programme should involve the dissemination of
aggregated data so that disease control and prevention can be enhanced 186. A good
surveillance system is required to be simple, flexible, acceptable, timely, sensitive to
detecting episodes of a condition, have a high positive predictive value, be
representative of the disease in a population and ideally to be cost effective 187. Data
collected from disease surveillance is useful for monitoring trends, identifying
emerging epidemics and describing and classifying new clinical syndromes. It allows
effective planning and implementing of control measures as well as allocation of
health resources appropriately. Surveillance can direct research and provides an
excellent base for policy decisions. Ongoing data collection helps to assess the
success or failure of control programmes.
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CJD surveillance in the United Kingdom
A historical perspective.
CJD surveillance in the United Kingdom began in England and Wales in 1979 with a
retrospective study attempting to identify all cases of CJD that occurred during the
previous nine years 188. The 152 cases identified in this study were ascertained from
three sources: death certificates, a previous study of pathologically-proven cases and
by direct notification from neurologists and neuropathologists. It is very likely that
underascertainment was significant during this period as there was no prospective
surveillance programme in place. It did, however, provide a starting point for CJD
surveillance in the UK. Most surveillance systems rely heavily on reports from health
care providers of suspected cases. Completeness of such "passive" reporting varies
considerably depending on the characteristics of the disease in question189, the
severity of the disease and its perceived public health importance 19°. Underreporting
may be exacerbated by a lack of knowledge of which diseases should be reported,
not knowing how to report appropriately, concerns about confidentiality and a
perception that the list of diseases to be reported is too extensive 191. The relatively
low profile of CJD at this time may have contributed to the lower incidence of the
disease observed during this period.
Criteria for the diagnosis of CJD (see Tables 1.9 and 1.10) were employed and cases
were classified as Definite, Probable or Possible on the basis of available clinical and
pathological information. The development of a standardized case definition is
important for any disease under scrutiny for diagnostic accuracy and to allow
comparison of data between centres. A case definition needs to be simple, acceptable,
understandable and have diagnostic criteria that are unambiguous 192. Since the
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inception of CJD surveillance within the UK the diagnostic criteria have undergone
several amendments (see Table 1.9,1.10 and 1.11) and these are discussed below.
The average annual incidence of CJD (which included sporadic and familial forms)
from the 1970-1979 retrospective study was 0.32 cases/million, with a peakmortality
rate in the 65-69 year age group. Clearly this figure is inaccurate as case
ascertainment during that period was limited. In 1980-1984 prospective surveillance
for CJD in England and Wales was initiated and an average annual mortality rate
(similar to incidence rates owing to the mean duration of illness of approximately
four months) of 0.49/million was detected 193. Patients were seen in life whenever
possible by a surveillance neurologist following voluntary referral from a clinician
with identification from death certificate notification and autopsy continuing. From
1970-1984 a total of 267 patients with definite or probable CJD were detected. There
was no space-time clustering of date and geographical location of onset. A case
control study undertaken with 72 of the cases and 144 age and sex-matched controls
did not find any evidence that cases had lived closer to each other than controls,
except that more cases had lived in London 193. Cases occurring between 1985 and
1990 in the UK were identified retrospectively.
The National CJD Surveillance Unit (NCJDSU) was established in Edinburgh in 1990
in response to the emergence of the epidemic of BSE in the late 1980s and upon the
recommendation of the Southwood report194. The primary aim of the NCJDSU was
to identify any change in the characteristics of CJD within the UK that might be
linked to the emergence of BSE. The previous surveillance data from the 1970s and
1980s were invaluable in providing a reference point for clinical and epidemiological
characteristics of CJD within the UK. The basis for re-establishing prospective CJD
surveillance rested on the premise that if BSE infected humans it would be most
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likely to cause disease manifestations similar to those already observed in CJD and
that some or all of the following phenomena might be observed195:
An increase in the overall incidence of CJD within the UK
An excess of cases in groups most likely to have high exposure to the causative agent
of BSE
A change in the epidemiological pattern of CJD, such as a change in the age
distribution
A change in the clinical or neuropathological characteristics of CJD
Case notification and data collection.
Since 1990, referral of suspect cases to the NCJDSU has continued in three ways:
Clinical passive ascertainment from neurologists, neuropathologists and
neurophysiologists. These groups of doctors are reminded annually of the need to
refer any individual with a possible diagnosis of CJD\
Death certificatesb. Passive ascertainment occurs with cooperation from the Office of
National Statistics for England and Wales and the General Register Offices for
Scotland and Northern Ireland. All death certificates coded under the rubrics
046.1(Jakob-Creutzfeldt disease subacute spongiform encephalopathy) and 331.9
" The underlying assumption from the targeting of certain professionals with reminders to refer is that the
clinical presentation of CJD will result in referral for a medical opinion and, ultimately, referral to a
neurologist19S. This assumption is borne out by work conducted in the UK and France66.
b The proportion of cases of sporadic CJD ascertained by death certificate has fallen from 13% in 1980-84
to 6% in 1990-92. For the years 2000 to 2001 only 2 cases of sporadic CJD were identified in this way. No
case ofvCJD to date has been identified solely by death certificate.
57
(other cerebral degenerations, unspecified) according to the 9th International
Classification of Disease revision are supplied to the NCJDSU.
Other sources. Passive ascertainment also occurs from psychiatrists, paediatricians,
geriatricians other health professionals and relatives.
CJD within the UK has not been made a notifiable disease as previous experience has
shown that statutory referral may not be the best way of detecting cases especially if
referral of unusual phenotypes is desired 25. A key aim of the surveillance unit is to
identify atypical cases 196. Due to the fact that the primary aim of the unit was to
identify cases of CJD that may have occurred as a result of BSE exposure, cases of
familial and iatrogenic CJD are not assessed in detail.
Case definitions.
The case definitions for both sporadic and variant CJD have undergone several
revisions since the NCJDSU was founded. The initial case definition for suspected
CJD was adapted from that developed by Masters et al in 1979 n7(see Table 1.9). This
relied on the presence of certain clinical features along with neuropathological
confirmation. In 1993 at the second meeting of the European Collaborative Study
Group on CJD, the criteria for sCJD were slightlymodified (NCJDSU minutes of
Rome surveillance meeting, unpublished) (see Table 1.10). The most recent
amendment to the sCJD criteria currently used in the UK and Europe took place in
1998 (NCJDSU minutes of Rotterdam surveillance meeting, unpublished) (see Table
1.11). It followed an analysis of the sensitivity and specificity of CSF 14-3-3 as a
diagnostic test and its subsequent validation 14S. Analysis of the final diagnosis of
those classed as Probable sCJD who subsequently had a postmortem examination
revealed that the current diagnostic criteria for Probable sCJD have a positive
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predictive value of 97% 14S. Autopsy confirmation of QD remains the gold-standard
in diagnosis.
The case definition currently in operation for vCJD was devised by a WHO working
group in Edinburgh in 2001 and is detailed in Appendix 1. To date all cases with a
diagnosis of Probable vCJD who have subsequently had postmortem examinations
have been confirmed cases.
The incidence of sCJD in the UK
An increase in the number of cases of sCJD has been observed in the UK since the
1970s. During the period of prospective surveillance in 1980-84 the yearly
number of deaths from sCJD in the United Kingdom averaged 24.8. During
prospective surveillance implemented after the onset of the BSE epidemic (1990-
1996) the yearly number of deaths averaged 33.6. From 1996-2002 the number of
deaths rose to a yearly average of 56 (NCJDSU data) as illustrated in Figure 1.2.
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These increases are largely thought to be due to improved case ascertainment and
had been anticipated 197 as methods of surveillance improved. The earlier work was
not likely to have been accurate in terms of calculating incidence. The increased case
numbers have predominantly been witnessed in the older age groups: case numbers
in patients over 70 years of age more than doubled from the period 1980-85 to 1990-
95195. A similar increase in numbers of sCJD has been observed in Europe, also
showing the differentially enhanced ascertainment in the older age group 118;119.
Concerns remain however that cases of both vCJD and sCJD in the elderly may be
being missed. Previous reports estimate that only about four per cent of elderly
patients dying with dementia have an autopsy 198. Concerns have been raised over
the impact of decreasing postmortem rates on the potential detection of CJD cases 199.
Figure 1.3 illustrates the number of deaths from sCJD from 1990-2003 according to
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Figure 1.3: Number of deaths from sCJD 1st May 1990-31st October 2003 according
to age group
24 29 34 39 44 49 54 59 64 69 74 79 84 89 +
age at death (years)
CJD Surveillance in Europe and other allied countries
The European Union (EU) prospective collaborative study of QD was initiated in
1993. This occurred largely as a result of the BSE epidemic and for the same
reasons that the NCJDSU was established in the UK. By the year 2000 Belgium,
France, Ireland, Netherlands, Portugal, and Switzerland had all reported cases of
BSE in their cattle albeit at much lower levels than in the UK. The collaborative
study has the additional aim of harmonizing research methods of national
surveillance across international borders and now includes some countries
outside Europe*. In addition to a further development of the case definition for
CJD 145 this work has led to comparative incidence studies 200-202 and analyses of
risk factors through case control studies 203-206.
*
Australia, Austria, Belgium, Canada, Finland, France, Germany, Greece, Iceland, Israel, Italy, the
Netherlands, Norway, Portugal, Slovakia, Spain, Sweden, Switzerland, UK, USA are all involved in this
programme.
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Table 1.9 Case definition of CJD according to Masters et al, 1979117
Definite CJD
Neuropathologically-confirmed spongiform encephalopathy in a case of progressive







Neuropathologically unconfirmed cases with the same clinical features described above
Possible CJD
History (without medical records allowing confirmation) of progressive dementia with:
A. Myoclonus and a course of less than three years; or
B. A member of the family having transmissible definite or probable CJD; or
C. At least two of the clinical features listed for definite CJD together with the
appearance of prominent and early signs of lower motor neuron involvement (the
amyotrophic form of CJD).
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At least two out of four of the following clinical features:
Myoclonus




Three out of four of the clinical features listed above
No EEG or an atypical EEG
Duration less than 2 years
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Table 1.11: Current Case definition for sCJD in the UK and Europe
I Rapidly progressive dementia
II a Myoclonus
b Visual or cerebellar features




Probable: I + 2 of II + III
or
Possible + positive 14-3-3




All patients included in this study had pathologically-proven sCJD and were known
to the NCDJSU. Patients were included who had been referred between January 1990
and the end of December 2002. Those cases referred at the end of 2002 but in whom
autopsy results were pending at the time of data collection were not included. Any
cases of suspect sCJD without neuropathological confirmation were excluded. The
total number of cases included in the study was 485. Cases were exluded if PRNP
mutation analysis revealed a mutation. Not all cases had complete mutation analysis.
Exact numbers of cases with full PRNP gene analysis are outlined in the results
section.
Cases referred to the NCJDSU with suspected CJD
Individuals with suspected CJD are referred to the NCJDSU either by passive
ascertainment from clinicians, death certificates (provided by the Office of National
Statistics) or from neuropathologists after a post-mortem examination revealed CJD.
Occasionally relatives or a member of the general public refer a suspect case.
Enquiries and referrals are dealt with initially over the telephone by a NCJDSU
doctor. Increasingly patients are referred initially for CSF 14-3-3 analysis but these
are not classified as "referrals" automatically (this depends on the clinical details of
the request).
When a referral of a suspect case is made a unique identification number is assigned
to that individual patient. If the patient is referred before death an assessment is
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made of the likelihood of CJD based on the clinical features and investigation results.
The patient is classified according to the case definitions for sCJD (see Table 1.11) or
vCJD (see Appendix 1) as a Definite, Probable, Possible or a likely "non-case". In this
study these classifications are denoted by a capital letter to differentiate them from,
for example, the possibility that the diagnosis may be CJD.
The definition of clinical subgroups
The following headings describe the patient groups that formed the basis of this
study:
Cases defined as "atypical" sCJD
Cases of sCJD only notified to the NCJDSU after autopsy
Cases classified as Possible sCJD who had not gone on to have an autopsy
Pathologically-proven Non CJD cases where CJD had been suspected in life
Defining "Atypical" sCJD
For the purposes of this study, cases that are defined here as Atypical shall, from
now on, be denoted with a capital letter "A". This is done in order to indicate that the
word refers to a strictly defined group of cases rather than an adjective that may be
used based on undefined criteria. In order to define Atypical sCJD it is important to
understand what constitutes a typical case. Features of a case of sCJD that are
generally considered typical include:
A short duration of illness (of less than six months)
An age of onset at around 65 years
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The presence of supportive investigations (namely periodic sharp wave complexes
on an EEG and a positive CSF 14-3-3)
An MM genotype
A presentation with dementia and the subsequent rapid evolution of symptoms
A Probable diagnosis when the clinical diagnostic criteria are applied
The aim of defining "Atypical" was to identify those cases of sCJD exhibiting
features that were unlike those typically associated with the disease. The features
considered in this process are as follows:
A long duration of illness.
One of the most striking features of sCJD is the rapidity of the physical and mental
decline that is often observed. Sporadic CJD cases with a longer illness durationmay
lack this characteristic rapid deterioration. When patients with sCJD live for longer
than two years other neurodegenerative conditions (such as Alzheimer's disease)
may be considered far more likely. Cases with a disease duration of greater than two
years are of particular interest in this study because they all fall outside of the case
definition for sCJD (which stipulates a disease duration of less than two years unless
the EEG is typical).
A young age at onset.
Young cases are unusual in sCJD and for this reason the diagnosis may not be
suspected initially. A young age at onset may lead to confusion with vCJD. Studying
these cases is important in understanding if the phenotype of sCJD is different in the
young and reasons why variability in phenotype may occur. Disease onset below the
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age of 50 years occurs in only about five per cent of cases: a sufficiently small
proportion for these cases to be regarded as Atypical.
The PRNP codon 129 genotype.
An association between a MV or VV genotype and unusual clinical features has been
described although authors have disagreed as to the extent of this correlation 87;207.
About 35% of patients with sCJD possess a MV orW genotype at codon 129. If all
these were taken to be Atypical on this basis alone then a large number of cases
would be involved. An alternative way of examining any association between
phenotype and genotype is to identify cases by unusual clinical features alone (i.e.
blinded to genotype) and then retrospectively examine the genotype results. This
method would eliminate selection bias in determining whether or not the hypothesis
was correct and was the method used in this study. Therefore codon 129 genotype
was excluded from the definition of an A typical case employed in this study.
Investigaton results: the EEG, CSF 14-3-3 and cerebral MR!.
A review of the results of EEG recordings undertaken on pathologically-proven sCJD
was performed in order to identify the proportion of positive and negative tracings.
It was found that only 39% of cases between 1990 and 2002 (who had had an EEG
recording performed) had exhibited a positive tracing. If a negative EEG was to be
included in any definition of Atypical it would result in the majority of cases (61%)
being considered Atypical on this basis alone.
CSF 14-3-3 has a sensitivity of 94% in cases with pathologically-proven sCJD referred
to the NCJDSU for CSF analysis34 and therefore a negative result is regarded as
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unusual. If CSF 14-3-3 was negative but all other clinical features were typical it
would be unlikely, in practice, to consider a case unusual on that basis alone. As
there are sometimes technical difficulties with the storage or transport of CSF
specimens a negative result in the context of an otherwise typical case may raise
doubts regarding the accuracy of the result. If unusual cases are identified on clinical
grounds alone and investigation results are examined subsequently then an
assessment of the role of the test in differing clinical scenarios can be made. For the
purposes of this study this approach is considered a better way of examining the role
of CSF 14-3-3 in Atypical cases.
It is not known whether or not basal ganglia high signal on cerebral MR correlates
with specific clinical features. This is assessed as part of this study but MRI findings
are not included in any definition of Atypical.
Unusual features at presentation and the delay in the onset of cognitive decline.
Typically sCJD presents with symptoms of a cognitive decline (e.g. memory loss,
confusion or disorientation). Other focal symptoms occasionally occur at onset
where impaired cognition is not a prominent early component. Visual symptoms
in isolation at onset are well recognised (the Heidenhain variant of sCJD) as are
predominant or virtually isolated cerebellar features (Brownell-Oppenheimer
form). Other focal onsets may cause diagnostic problems if cognitive decline is
delayed, for example the presentation with an isolated involuntary movement or
a pure psychiatric symptom. Assessing whether cognitive decline is delayed is
largely dependent on the clinical history from any family and documentation by
involved clinicians. Many patients would not undergo detailed
neuropsychological testing and therefore the judgement as to whether a
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cognitive decline is present or absent is largely a clinical one. Psychiatric
symptoms alone, for example, may not be perceived as representing a cognitive
decline, as is often the case in vCJD. Cases exist that are not typical for sCJD
because of the perceived absence of any cognitive decline (usually early in the
illness).
By defining unusual clinical presentations (such as pure visual, pure cerebellar or
cases where an apparent cognitive decline is delayed) it is possible to assess the
amount of diagnostic difficulty caused. It also enables an assessment of whether
disease presentation is a marker for an unusual disease progression.
Cases not given a Probable or Possible diagnosis according to the current
clinical diagnostic criteria.
Any group that does not meet the clinical diagnostic criteria for sCJD is likely to
include a number of clinically unusual cases. The problem of incomplete data, due to
a lack of available medical information, prevents any analysis of this group being
meaningful. If a patient is referred but clinical data are sparse they often do not meet
the criteria for a Possible case. Some patients are not examined neurologically whilst
unwell and in other instances access to medical notes may be denied or problematic.
This category would be likely to include a significant number of patients with poor
clinical information who may or may not be clinically Atypical.
A summary of the definition of an Atypical case used in this study
An Atypical case of sCJD was defined in this study according to the following
characteristics:
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A duration of illness of two years or more
An age at onset of less than 50 years
Presentation with pure visual symptoms in isolation for at least two weeks
Presentation with a cerebellar syndrome and no evidence of a cognitive decline* for at
least one month into the illness
Presentation with another focal symptom (i.e. not visual or cerebellar) and no
evidence of a cognitive decline* for at least one month into the illness
A comparison group: "Core sCJD"
In order to make comparisons regarding Atypical cases a group of pathologically
proven sCJD cases who were not Atypical were identified. They are referred to here
as "Core sCJD". The defining characteristics of this group were the presence of all of
the following:
Age at onset 50 years or more
Duration of illness less than two years
Documented evidence of a cognitive decline within the first month of the illness
Not presenting with visual symptoms only for the first two weeks of the illness
One hundred and thirty three cases of pathologically proven sCJD were identified
consecutively, who met with these criteria, starting with the most recent cases
(diagnosed at the end of 2002) and working backwards. Cases were included if
sufficient clinical information was available for a "Patient review and examination
form" to have been completed. This ensured a certain level of information was
available so that direct comparisons could be made. The author and a member of the
*
Where cognitive decline is defined as memory loss, forgetfulness, confusion or disorientation and its
absence was based on positive documentation (rather than the absence of comment) that it was not present
according to the assessing clinician and the family.
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administrative staff at the NCDJSU extracted clinical data for each of the patients
identified in this group. Prior to the point in time where the more recent "Patient
review and examination form" was introduced (1997) patients were not included in
the Core group. This point was chosen as it was difficult for the non-medically
trained researcher to interpret the written clinical histories and add the required
information to the database. The information included in the database for this Core
group is summarized in Table 2.1 along with the information collected for the other
subgroups studied.
Data Collection
Data collection within the surveillance framework
Much of the raw data for this study was drawn from the NCJDSU archive, which had
involved the work of 11 doctors* over the 12 year period, 1990-2002. The author
collected data from individual cases referred from December 2001 until the end of
December 2002 by visiting the patients and their families. The procedures involved in
a visit are detailed below. The extraction, by the author, of specific data for this study
from the NCDJSU archive shall be considered separately.
*
RobertWill, Richard Knight, Tom Esmonde, Rajith de Silva, Martin Zeidler, Gillian Stewart, Margaret-
Ann MacLoed , Andrea Lowman, Colm Henry, Sarah Cooper, Craig Heath.
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Assessment of suspect cases
Whenever possible all referrals categorised as Definite, Probable or Possible QD are
visited in life by a neurologist from the NCJDSU and a research nurse. A visit is only
made with consent from the referring clinician, the family and, if feasible, the patient.
For patients who are not visited in life, or for those where notification came after
death, a visit to the family is still undertaken whenever possible to discuss the
clinical history and to collect clinical and epidemiological information. If the family
or the clinician is unhappy for a visit to take place then hospital and general
practitioner records are requested for review (with the consent of the family).
Collection of clinical, epidemiological and neuropathological information.
Patients and their families are visited in order to make a more detailed assessment of
the clinical features of the illness and also to gain further epidemiological
information and provide the family with information about CJD. A visit to assess a
suspected case involves:
The completion of a "Patient review and examination form"* (see Appendix 3)+. This
includes a detailed clinical history from the patients' relatives, with the addition of
any further information from the medical notes. A full neurological examination is
*
If a patient is not seen in life then a "Late referral form" is completed with the family after death. This
involves obtaining a history in the same way but relies on previous medical documentation for clinical
examination findings.
+
Efforts have been made to standardize the information gathered by the use of two proformas for the
recording of clinical signs (one pre-1997, one introduced in 1997). The latter proforma allows for greater
uniformity of data as symptoms and signs are specifically recorded along with their date of onset (see
Appendix 3). The earlier proforma does provide an outline for the recording of clinical details although it is
less structured.
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carried out by the NCJDSU doctor and recorded in this form in a standardised way
that ensures that the same information is collected for each patient. Information
regarding clinical examination from the medical notes is added (with consent) in a
separate section.
The completion, with the family, of a risk factor questionnaire as part of an ongoing
case-control study.
In the majority of cases this is the responsibility of the research nurse and the
questions are answered by one nominated family member (usually the next of kin).
A discussion regarding the potential diagnosis and its implications.
This would usually include giving information regarding the possibility of genetic
CJD. Information produced by the CJD support network and, in cases of suspect
vCJD, the Human BSE foundation is offered to the family.
With the family's consent a blood sample is taken for genetic analysis and research
purposes
Copies of MRI scans and EEG recordings are requested for each patient and are then
reviewed by experienced staff at the NCJDSU. EEGs are graded according to a five-
point scale (normal, non-specific, suggestive, highly suggestive and typical) by one
or more experienced observers blinded to the diagnosis (see Appendix 2). Each MRI
scan is examined for features associated with CJD (as described in Chapter 1) or
additional abnormalities, which may suggest other diagnoses. A NCJDSU doctor
requests follow up information about each patient from the referring clinician. If a
patient dies the NQDSU asks to be informed of any decision regarding a post¬
mortem examination and any subsequent findings.
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Classification.
Suspect cases are classified as CJD unlikely, Possible, Probable or Definite CJD by the
NCJDSU according to current diagnostic criteria (Table 1.9). The classification may be
updated as more information is gathered. The date of any change to the classification
and the reasons for the change is recorded. The patient classification is noted:
1. At notification to the NCJDSU
2. When the suspect case was first seen in life by a neurologist from the NCJDSU
3. As the highest classification on the basis of clinical information alone (i.e. not
including neuropathological information)
4. When review by the NCJDSU is complete (i.e. when a case file is closed)
The majority of the clinical information gathered was obtained through prospective
surveillance with patients being assessed by an experienced NCJDSU observer. If a
patient was notified after death then the clinical information recorded in the NCJDSU
database was reliant on observations made by local medical staff. Many other studies
have relied solely on retrospective information from other observers which is likely
to have problems with intra observer variability and may mean that more subtle
clinical signs are overlooked.
A main objective of the study was to identify and characterise defined clinical
subgroups within the sCJD cohort. For the purposes of this research individual
subgroups were defined (see below) and an individual case-file review was
performed (by the author) on each patient. Relevant data (see Table 2.1) was
extracted by the author, stored and identified by number only in Excel files to ensure
confidentiality.
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Applying the definition ofAtypical
Those patients with an age at onset of less than 50 years and a duration of illness of
two years or more were identified by an inspection of the NCJDSU database of the
485 pathologically proven cases where age and duration of illness are recorded
numerically. These cases comprise the "long duration" and "young" sCJD
subgroups.
Identifying clinical phenotype at presentation.
Features relating to disease presentation were identified by individual case file
review. The clinical history in the 485 case files was reviewed on two separate
occasions (to ensure that no cases were missed on the first review) by the author to
identify presenting features. This procedure also served as a comprehensive survey
of first symptoms in all pathologically confirmed sCJD cases. Each case file contains a
written history (taken by an NCJDSU doctor) with emphasis placed on first
symptom. In the proforma used after 1997 for each patient a separate section exists
where the "first recorded symptom" is stipulated. Prior to 1997 this information is
gained from the written clinical history.
Cases were identified where the first recorded symptom was visual or cerebellar*.
Cases were then excluded from further analysis if a) visual onset cases had any other
symptoms for the first two weeks or b) if cerebellar onset cases were documented as
having symptoms of memory loss, forgetfulness, confusion or disorientation during
the first month of their illness (i.e." cognitive decline").
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In addition, those with another (i.e. not visual or cerebellar) focal onset were also
identified if symptoms representing cognitive decline (i.e. confusion, forgetfulness,
memory loss or disorientation) were absent for the first month of illness. Examples of
cases with "another focal onset" would include patients whose presenting complaint
was of a sensory disturbance or an involuntary movement.
It is recognised that a cognitive decline may have been present in some of these cases
in the early stages but manifest in other ways (for example depression). The purpose
of identifying Atypical cases in this way was to identify cases that could potentially
cause diagnostic problems because they were not perceived as being cognitively
impaired in the early stages. Therefore cases were not excluded from the atypical
groups on the basis of psychiatric or behavioural symptoms if there was no
associated cognitive decline (as defined above) and they were not perceived as being
cognitively impaired.
Compiling a database forAtypical cases
Once identified each Atypical case was studied in more detail and certain clinical
parameters were noted. These variables can be summarized as: clinical features,
investigation results, timing of referral and clinical diagnosis in life. A breakdown of
all the features noted for each case is found in Table 2.1.
Cerebral magnetic resonance imaging in Atypical cases.
"
Cerebellar symptoms were defined as gait unsteadiness, ataxia, a broad-based gait, clumsiness or falls,
nystagmus or cerebellar dysarthria
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The role of cerebral MRI in Atypical cases was assessed by reviewing all MR
films in the NQDSU archive on cases meeting the definition of Atypical (n=30).
MRI was not included at the outset as a criteria for an Atypical case as any
association with unusual clinical features is unknown. Another aspect of this
study was to assess scans from clinically Atypical cases. These were matched
according to within one year of scan date with scans from patients who did not
possess Atypical features. This matching was done because of the variation in
scan quality seen (particularly in the earlier MR sequences) as an attempt to
ensure comparability of image quality. Age at onset, illness duration and the
presence of specified clinical features (myoclonus, pyramidal signs,
extrapyramidal signs, sensory symptoms, involuntary movements, visual
symptoms/signs and cerebellar features) were noted for each patient whose scans
were reviewed. Clinical features and the presence of abnormalities on the scans
were assessed to look for any correlations.
Cases only notified to the NCJDSU after autopsy
A database is kept at the NQDSU of the occupation of the individual who first
notified any individual patient. Using this database all those cases were identified
who were referred to the NQDSU by neuropathologists. Those notified after death
but before the results of an autopsy were known were not included in this group.
Clinical data was noted for each case by a review of individual case files conducted
by the author. The nature of this data is outlined in Table 2.1.
Cases classified as Possible sCJD who had not gone on to have a
postmortem examination
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These cases are not included in the national incidence figures for sCJD as the
diagnosis remains uncertain. They are denoted here as Possible with a capital letter P
to indicate they are Possible according to the diagnostic criteria rather than "it is
possible they may have CJD". In life these cases were classified as Possible sCJD
according to diagnostic criteria but neuropathological confirmation/ exclusion of the
diagnosis was not performed. They were identified by a review of the computerised
NCJDSU archive which holds data on the final classification of patients. Once the
individual patients classified finally as Possible were known the author reviewed
each case file and clinical data was extracted and used to compile a separate
database. The data collected is summarised in Table 2.1.
Pathologically proven non-cases where CJD had been suspected in
life
Patients referred to the NCJDSU with suspected sCJD between 1990 and the end of
2002 who ultimately had an alternative diagnoses proven at autopsy were identified
by a review of final case classifications. Amongts these cases some were considered
sufficiently likely to have CJD to warrant an assessment by an NCJDSU doctor. Cases
visited in life by a NCJDSU doctor formed a group that were studied individually by
retrospective case file review and were termed "clinically-selected non-cases".
Clinical information was extracted as outlined in Table 2.1.
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Table 2.1: Data collected for each of the subgroups in this study
All Atypical Core sCJD Cases Possible Non-
sCJD cases sCJD /vCJD referred sCJD sCJD
group after (clinically
Feature recorded autopsy selected
Final autopsy diagnosis X * * * *
X
Age at onset X X
X X X X X
Age at death * X * * X
X X
Gender X X X X X X X
Illness duration X X X * X X X
sCjD suspected in life * * X X X X
Final classification in X X X X X
life
Presenting symptom X X X X X X X
Presence of:
Dementia X X * X X X
Myoclonus X X X
* X X
Cerebellar signs X X X X
X X
Visual disturbance X X * * X X
Extrapyramidal signs X X X X
X X
Pyramidal signs X X *
X X X
Involuntary movements X X X
X X X
Sensory symptoms X X X
X X X
Seizures * * X X X X
Psychiatric symptoms X X * X
X X
Why sCJD suspected X
Number of EEGs * X X X X
Timing of EEG X X
X X X
Result of EEG(s) X X * X X X
X
Clinical features at EEG X X X X X
CSF 14-3-3 result * X X X X X X
MRI brain result X X X X X
Timing of MRI brain X * X
X X




specialist referral * X
X
referral to NCJDSU X X X
Reasons for non referral X
Neurologist involved? X
X
Year of referral of case X X X * X- X X
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Data Analysis
Statistical analysis was performed using Intercooled Stata version 8. Statistical
advice was sought from a statistician employed by the NCJDSU.
Analyisis of Atypical cases
Clinical features.
Presenting features were documented in young and long duration sCJD cases
allowing a direct comparison with those seen in sCJD as a whole in other studies.
Parametric tests (Chi squared or Fisher's exact depending on the sample size) were
employed to examine any statistically significant differences between symptoms at
onset in these group compared with those seen in the comparison Core group of
sCJD.
For each of the Atypical subgroups the proportion of patients displaying specific
clinical features was calculated. For each symptom or sign the observer is asked to
record its' presence as Yes, No or Not Sure on the standardised proforma used by the
NCJDSU. For the purposes of this study the Not Sure values were included in the No
group. Proformas used before 1997 did not include Not Sure as an option (just Yes
and No).
The prevalence of specific clinical features observed throughout the illness was
compared between each Atypical subgroup and the Core group. Chi squared and
Fisher's exact tests were applied (depending on the sample size of the group) to
assess the statistical significance of the differences observed. For each Atypical
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subgroup the parameters of age arid illness duration mean, median and the range
were calculated. Non parametricWilcoxon ranksum Tests (MannWhitney U test)
were applied to assess if there was a significant difference between the ages and
duration of illness seen in the Atypical subgroups and the comparison Core group.
By doing this the clinical phenotype of each subgroup could be established and
compared with that observed in more typical sCJD (as defined by the Core group).
Clinical features in the Core group were also tabulated against those seen in other
studies examining clinical features in sCJD.
The age at onset and duration of illness for cases in each of the Atypical subgroups
was compared graphically with the Core group using scatter plots and
mathematically by employing the Wilcoxon rank sum test.
A closer examination of each long duration case of sCJD was performed. Each case
file was examined thoroughly for information relating to the pattern of decline in any
individual patient. Certain clinical parameters were defined as being markers of
decline (onset of confusion, loss of ability to wash and dress independently, speech
problems and mutism, incontinence, myoclonus, swallowing problems,
immobility/becoming bed bound) and timings of the onset of problems in these areas
were documented where known. This helped to gauge whether the long duration
cases exhibited a generally slower overall decline or whether they declined
physically at a fast rate but were sustained for long periods in a physically-
dependent state.
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Investigations in Atypical subgroups.
The prevalence of positive EEGs recorded amongst patients in each of the Atypical
subgroups was established using defined EEG classification criteria (Appendix 2).
Fisher's exact test was employed to assess differences in the prevalence of positive
recordings between the Atypical groups and the Core group. The age and duration of
illness in cases with positive recordings was compared with those with negative
recordings using the non-parametricWilcoxon ranksum test. The timing of the EEG
recordings was tabulated.
Due to the small numbers involved and because a proportion of samples were
unsuitable for analysis, CSF 14-3-3 results were not compared statistically between
the subgroups. The presence of high signal in the caudate head and putamen on
brain MRI was compared between cases displaying Atypical features and a
comparison group matched for scan date using a Chi Squared test. The age and
duration of illness of cases with high signal in these structures versus those with
normal signal was compared using a Wilcoxon ranksum test.
The distribution of the genotype observed at codon 129 of the PRNP gene was
compared between the Core group and each Atypical subgroup using Fisher's exact
test.
Referral patterns and classfication.
The timing from disease onset to referral of cases to the NCJDSU was compared
between Atypical subgroups and the Core group using the Wilcoxon ranksum test.
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The proportion of cases classified as Possible, Probable and Definite was also
compared between groups using Fisher's exact test.
Analysis of cases referred after autopsy
These cases were divided into those in whom the diagnosis of sCJD was
suspected and those in whom it was not suspected. The clinical features were
described for each group and the proportion of Atypical clinical cases amongst
the groups is documented. The age and duration of illness of cases referred after
autopsy is compared with that seen in cases referred before autopsy using the
Wilcoxon ranksum test. The frequency and results of relevant investigations are
described. The input of neurologists in diagnosis and the frequency of case
referral over time is described.
Analysis of cases finally classified as Possible sCJD
The distribution of these cases over time is described along with the way that
relevant investigations are utilised.
Non cases
Alternative diagnoses in this group of cases originally suspected of having sCJD are
described. A clinically-selected group of cases is considered separately. Duration of
disease in these cases is compared graphically with that seen in pathologically-
proven sCJD cases. The clinical features of those with a final diagnosis of Alzheimer's
disease are described separately.
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CHAPTER 3: RESULTS
Presenting features in sCJD
Clinical data on the 485 neuropathologically proven cases of sporadic CJD known to
the NQDSU (1990-2002) were reviewed to identify the first recorded symptom. The
most common presenting symptoms were those of memory loss, confusion,
disorientation or forgetfulness reported in 151 (31%). Problems with gait related to
unsteadiness or ataxia occur at onset in 128 (26%) of cases. When psychological and
psychiatric features are combined (to include anxiety, agitation, irritability,
aggression, personality change, behavioural change, depression, paranoia,
hallucinations and suicidal ideation) they were present at onset in 85 (18%) of
patients. There may be difficulties with some of the terms used in the case files such
as "behavioural change" which could result from a problem with memory or
cognition or from a psychiatric disturbance such as anxiety (factors which are often
not clearly defined for each individual case). In some cases a patient presents with
more than one symptom and the full results are presented in Table 3.1.
Table 3.2 compares common presenting features between studies. It should be borne
in mind that other studies may have used a term such as dementia to represent not
only memory loss, forgetfulness or confusion but also psychiatric features, making
direct comparisons difficult.
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Table 3.1: First recorded symptom in 485 pathologically proven cases of sCJD
Presenting symptom Number of patients (% to nearest whole
number in brackets)
N=485
Memory loss, forgetfulness, confusion or 151 (31)
disorientation
Unsteadiness/falls/ataxia 128 (26)
Visual disturbance 42 (9)
Dizziness/vertigo 38 (8)
Personality/behavioural change 33 (7)
Anxiety/irritability/aggression 31 (6)
Sensory symptoms 30 (6)
Speech problems 29 (6)
Sleep disturbance 28 (6)
Involuntary movements 26 (5)
Limb weakness 14 (3)
Depression 13 (3)
Headache 12 (3)
Handwriting difficulties 6 (1)
General slowing 6 (1)
Deafness 5 (1)
Weight loss/loss of appetite 5 (1)






Suicidal ideation 1 (<1)
Amnesic episode 1 (<1)
Information regarding disease onset 7 (1)
unavailable
*
Two cases were involved in minor accidents, two cases became lost whilst driving and one had difficulty
coordinating the car's controls
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Table 3.2 A comparison of presenting features in sCJD between this study and six


























(n=485) (n=124) (n= 137) (n=230) (n=232) (n=144) (n=122)
% pathologically
confirmed







Dementia 29 21 31 61 50


















Headache 3 10 3 7 11
Sensory 6 2 4 5 6 3 4




4 1 5 <1 4 1 2
a
These studies include between four and ten percent familial cases
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"Atypical" sCJD
Atypical cases shall be considered under the following headings:
Young cases (with an age at onset of less than 50 years)
Long duration cases (with a duration of illness of greater than or equal
to two years)
Pure visual onset cases (cases with reported visual symptoms only for
the first two weeks of the illness)
Cerebellar onset cases (those presenting with a cerebellar syndrome
in the absence of cognitive decline (i.e. memory
loss, forgetfulness, confusion or disorientation
for at least one month into the illness)
Other focal onsets (those with symptoms other than cognitive
decline, or those defined above, for at least the
first month of the illness)
Comparing Atypical sCJD to sCJD without Atypical features ("Core
sCJD")
In order to make comparisons between clinical features seen in typical cases and
those seen in other cases of sCJD a group of patients were selected to represent a
Core group of sCJD. This group comprised of one hundred and thirty three
consecutive cases of pathologically proven sCJD without defined Atypical features
(working chronologically backwards from the end of 2002). The mean age at onset in
this core group was 69 years (median 69 years, range 50-94 years) and the mean
duration of illness was 5.5 months (median 4 months, range 1-22 months). By
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definition the patients had to be fifty or more years old and have a disease duration
of less than two years.
The clinical features present in this group are summarized in Table 3.3 and a
comparison is made with the incidence of features seen in cases in other large studies
in Table 3.4. As any case with Atypical features (as defined by our study) has been
excluded, the comparison with other studies is limited (as these would have not
excluded unusual cases). Visual symptoms for example are less common in the Core
group when compared with some other studies, which is likely to reflect the
exclusion of any cases with a pure visual onset.














Table 3.4: Clinical features present throughout the illness in a Core group (n=133)




























































































64 44 79 (inc
rigidity)










10 7 11 16
Seizures 9 9 9 8 19 13 28 12
a
These studies include between four and ten per cent familial cases
90
Clinical features ofAtypical cases
One hundred and fifteen patients (24%) out of 485 pathologically proven cases of
sCJD met one or more of the criteria for an Atypical case. The proportion of cases in
each Atypical subgroup is displayed in Figure 3.1. Eighteen patients (four per cent)
met with the definition of more than one category (e.g. young with a long duration of
illness) and the overlap of Atypical features displayed by these patients is
summarized in Figure 3.2. There were 55 men and 60 women (male to female ration
of 1.0 :1.1) who had one or more Atypical feature. The mean age at onset in the total
Atypical group was 58 years (range 15-88 years) and the mean duration of illness was
13.3 months (range 2-74 months). The combined total of all the Atypical subgroups is
133 (18 patients appear in more than one group).
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cerebellar visual other focal
onset onset onset
Figure 3.2: Venn diagram displaying the overlap with cases that possess more
than one Atypical feature (n=18)
(The numbers in each section indicate the number of patients)
92
Young cases.
A young case of sCJD is defined, for the purposes of this study as a patient with
pathologically proven sCJD whose first symptom was recorded below the age of 50.
Thirty four patients out of 485(seven per cent) fell into this category.
Sixteen of the patients were male, 18 were female. The mean disease duration in this
group was 18.7 months (median 11 months, range 2-60 months). The age distribution
amongst young cases is summarized in Table 3.5 (two cases occurred under the age
of 30 years). Duration of illness was not compared directly with the Core sQD group
as these all had disease durations of less than two years by definition. One patient is
not included in any further analysis, as the case notes were unavailable at the time of
this study. PRNP gene mutation analysis (excluding genetic CJD) was performed in
27/34 (79%).
Table 3.5: Age distribution of young cases









The first observed symptoms in the young cases are summarized in Table 3.8 and
a comparison is made with those seen in Core sCJD. It is less common for young
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cases to present with unsteadiness/falls/ataxia compared with Core sCJD
(p=O.028, Fisher's exact test). It is more common for the younger patients to
present with personality/behavioural change when compared with Core sCJD
(pMl.0015, Fisher's exact test). There was no statistically significant difference
between other presenting features amongst young and Core sQD cases.
The proportions of young patients with specific clinical features throughout the
illness are summarized in Table 3.6. Young cases, when compared with the Core
group (n=133), were more likely to exhibit psychiatric features (p^O.OOl, chi
squared test) and involuntary movements other than myoclonus ^=0.016, chi
squared test) during the course of the illness. Young cases were less likely to
display cerebellar features (p=0.004, chi squared test) and extrapyramidal signs
(p=<0.001, chi squared test) than those in the Core group. These features and
those seen in other Atypical groups when compared with the Core group are
summarized in Table 3.7.
Table 3.6: Clinical features in young cases












Table 3.7: Statistically significant differences between clinical features seen
through the course of the illness in Atypical sCJD subgroups versus Core sCJD
(n=133)





than in Core sCJD
P value Clinical features seen
less often than in Core
sCJD
P value
Young Psychiatric features <0.001 Cerebellar signs 0.004
Involuntary Extrapyramidal signs <0.001
movements (other 0.016
than myoclonus)
Long Psychiatric features <0.001 Cerebellar signs 0.014
Extrapyramidal signs 0.031
Pure cerebellar Visual disturbance <0.001
onset Psychiatric features 0.0012
Sensory symptoms 0.008A
Pure visual onset Extrapyramidal signs 0.002^
Cerebellar signs 0.0011A
Other focal onset Sensory <0.001 Extrapyramidal signs 0.002
associated with a disturbance Cerebellar signs 0.008
delay in the Psychiatric 0.013
onset of symptoms





Long duration sCJD is defined in this study as a pathologically proven case of sCJD
with a disease duration of greater than or equal to two years. Twenty eight patients
out of 485 (six per cent) with pathologically proven sCJD died two years or more
after disease onset. Three patients were alive at the time of the study therefore their
disease duration is, as yet, unknown. Therefore 28/482 (6%) of sCJD patients had a
disease duration greater than or equal to 24 months*. This is illustrated in Figure 3.3.
The mean age at onset in this group was 54 years (median 54 years) with a range of
15 years to 75 years. Thirteen of the patients were men and fifteen were women.
PRNP gene mutation analysis (to exclude genetic CJD) was performed in 15/28 (54%).
None of the remainder had a family history of CJD.
*
Illness duration was not documented to the nearest month in 14 cases. This was often due to a lack of
precise information as to disease onset or date of death. However, on review of these case notes it was
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(Cases are included where disease duration was known to the nearest month (n=468))
Presenting features in long duration cases are compared with those seen in the Core
group of sCJD in Table 3.8. Personality or behavioural changes are more common at
onset in long duration cases than in other sCJD (p = 0.002, Fisher's exact test) as is
depression (p=0.037, Fisher's exact test). Unsteadiness, falls or ataxia are less common
at onset in the long duration cases (p=0.04, chi squared test,). The proportions of long
duration cases with specific clinical features throughout the whole illness are
summarized in Table 3.9. Long duration cases are compared with the Core group of
sCJD (n=133) and are more likely to exhibit psychiatric symptoms (p=<0.001, chi
squared test). They are less likely to display extrapyramidal signs (p=0.03, chi
squared test) or cerebellar signs (p=0.014, chi squared test) throughout the course of
the illness (see Table 3.7) when compared with the Core group.
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Table 3.8: Presenting features in young and long duration sCJD compared with
sCJD as a whole (percentages to the nearest whole number in brackets).
Presenting symptom Young Long duration Core sCJD Total sCJD
cases (n=33) sCJD (n=28) (n=133) (n=485)
Cognitive decline (memory loss, 11 (33) 15 (54) 56 (42) 151 (31)
confusion, disorientation)
Unsteadiness/falls/ataxia 2 (6) 2 (7) 31 (23) 128 (26)
Visual disturbance 1 (3) 0 6 (5) 42 (9)
Dizziness/vertigo 1 (3) 0 11 (8) 38 (8)
Anxiety/irritability/aggression 5 (15) 4 (14) 9 (7) 31 (6)
Sensory symptoms 3 (9) 1 (4) 2 (1) 30 (6)
Speech problems 3 (9) 1 (4) 12 (9) 29 (6)
Sleep disturbance 1 (3) 3 (11) 3 (2) 28 (6)
Involuntary movements 2 (6) 1 (4) 4 (3) 26 (5)
Personality/behavioural change 4 (12) 5 (18) 2 (1) 19 (4)
Limb weakness 0 0 3 (2) 14 (3)
Depression 3 (9) 3 (11) 2 (1) 13 (3)
Headache 1 (3) 0 1 (<1) 12 (3)
Handwriting difficulties 1 (3) 0 2 (1) 6 (1)
General slowing when 2 (6) 1 (4) 2 (1) 6 (1)
performing daily activities
Withdrawal/loss of interest 1 (3) 0 2 (1) 5 (1)
Deafness 0 0 0 5 (1)
Weight loss/loss of appetite 1 (3) 0 2 (1) 5 (1)
Problems driving a car 0 1 (4) 2 (1) 5 (1)
Paranoia 0 1 (4) 1 (<1) 4 «1)
Blackout/seizure 1 (3) 0 1 (<1) 3 (<1)
Nausea/vomiting 1 (3) 0 1 (<1) 3 «1)
Tinnitus/earache 1 (3) 0 0 3 (<1)
Hallucinations 0 0 2 (1) 3 (<1)
Suicidal ideation 0 0 0 1 (<1)
Amnesic episode 0 0 1 (<1) 1 (<1)
Information re. onset unavailable 1 (3) 1 (4) 2 (1) 7 (<1)
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Seven of these patients (25%) were still able to walk at 24 months. Only two of the 28
patients had lost the ability to walk before one year (one at four months and one at 11
months). Five out of the 28 patients in this group (18%) still had some degree of
speech at 24 months. Clinical parameters are recorded, where known, according to
their presence/absence at six monthly intervals and summarized in Table 3.10. Figure
3.4 illustrates how far into the illness individuals developed problems with gait and
when they were last recorded as walking (their ability to walk may have continued
beyond this point and not been recorded in some cases). In most cases of sCJD (with
death occurring within six months) gait disturbance is prominent and early. The long
duration cases seen here have, with one notable exception*, a genuinely slower
disease progression rather than a rapid progression with many months of being
sustained in an akinetic and mute state.
*
In one highly unusual case the patient was akinetic, mute and bed bound by four months but lived for a
total of 54 months. This patient was also the youngest patient in our series (15 years old at disease onset).
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Table 3.10: The progression of clinical features in sCJD of long duration (n=28)
TIME SINCE ILLNESS ONSET (MONTHS) WHEN SYMPTOM EMERGED
CLINICAL 0-6 7-12 13-18 19-24 >24 Unsure Total no.
FEATURE of
Number of patients patients
Confusion/ 21 4 0 0 0 3 28
forgetfulness
Unable to 2 4 6 4 3 9 28
wash/dress
Became bed 1 1 3 7 7 9 28
bound
Developed 1 0 4 4 4 15 28
incontinence
Developed 1 2 3 4 5 13 28
myoclonus
Speech 9 1 6 2 3 7 28
problems first
noted
Became mute 1 1 2 3 5 16 28
Developed 1 0 2 3 7 15 28
swallowing
problems
Figure 3.4: Duration of illness and timing of immobility in 23 long duration cases
Illness duration is represented by the vertical line, in cases where information regarding
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Cases presenting with a cerebellar syndrome in the absence of early cognitive
decline.
These cases were defined as individuals presenting with features of cerebellar
dysfunction in the absence of any documented memory loss, confusion
forgetfulness or disorientation for at least one month from symptom onset.
Twenty five (five per cent) of the 485 patients met with this definition. Although
26% of the total sCJD cohort presented with unsteadiness or ataxia this was also
often associated with an early decline in cognition and therefore not included
here.
There were seventeen men and eight women. The mean age at onset was 64
years (median 62 years, range 48 to 76 years). The mean duration of illness was
9.5 months (median 8 months, range 2-36 months). All but one were aged over 50
years of age at disease onset. PRNP gene mutation analysis (to exclude genetic
CJD) was performed in 14/25 (56%). None of the remainder had a family history
of CJD.
The predominant early features of the illness were of unsteadiness and poor
coordination in all. The very first documented symptoms were of gait
unsteadiness in 17, dizziness in five and poor coordination in two. In three of the
25 (12%) there were associated sensory symptoms at presentation (burning
sensations in the left upper and lower limbs in one and parasthaesia in the back
in two). Two also had visual symptoms at onset (one blurred vision, one double
vision), one also complained of headache and one of excessive tiredness. The
proportions of patients with specific clinical features throughout the whole
illness are summarized in Table 3.11. When compared with the Core sCJD group
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these patients were found to be more likely to exhibit visual disturbance
(p=<0.001, chi squared test), sensory symptoms (p=0.008 Fisher's exact test) and
psychiatric symptoms (p=0.0012, chi squared test) (see Table 3.7).
Table 3.11: Clinical features in cerebellar onset cases











Cases presenting with isolated visual symptoms.
This group was composed of patients presenting with pure visual symptoms that
persisted for at least two weeks into the illness in isolation (i.e. with no other
documented symptoms or signs).
Nineteen patients out of 485 (4 per cent) met this definition and were included in this
group. Seven of these patients were men and 12 were women. The mean age at onset
was 67 years (median 65 years, range 50-88 years). The mean duration of illness was
4 months (median 3 months, range 1-17 months). Fifteen (79%) patients had an illness
duration of 3 months or less. Disease duration was more likely to be shorter in the
pure visual onset group than that observed in Core sCJD (p=0.015, Wilcoxon rank
sum test) despite the fact that the Core group excluded long duration cases by
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definition. PRNP gene mutation analysis (to exclude genetic QD) was perfomed in
13/19 (68%).
The most common visual disturbance was of worsening visual acuity (although
blurred vision, visual distortions, visual field loss, dyschomatopsia, visual
delusions and palinopsia are also described) (see Table 3.12). The proportions of
patients with specific clinical features throughout the whole illness are
summarized in Table 3.13. When compared with a core sCJD group these
patients were less likely to exhibit extrapyramidal signs (p=0.002, Fisher's exact
test) and cerebellar features (p=0.0011, Fisher's exact test) (see Table 3.7).
Table 3.12: Description of visual symptoms at onset in pure visual onset cases
Symptom at onset No of patients (total n=19)
Worsening visual acuity 7
Blurred vision 5
Visual distortions 4
Visual field loss 2
















Cases presenting with other focal symptoms and a delay in the onset of cognitive
dysfunction.
This group comprised of cases presenting with focal features (excluding a pure
cerebellar syndrome or isolated visual problems as these are considered separately)
and no documented memory loss, forgetfulness, confusion or disorientation for at
least one month. Included in this group were ten patients who presented with
psychiatric symptoms*. It is recognised that these symptoms may be early features of
a dementia but they have been included here as, in the absence ofmemory loss,
forgetfulness, confusion or disorientation they were considered to represent a
psychiatric phenomenon by the involved clinicians. Twenty seven patients (6 per
cent) were found who clearly met with this definition according to the available
documentation. Cases were not included where the presence or absence of a
*
Defined as depression, anxiety, apathy, withdrawal, delusions (these characteristics are the same as those
listed in the vCJD diagnostic criteria)
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cognitive decline was ambiguous. Presenting features in this group are summarized
in Table 3.14.
Seventeen of these patients were women and 10 were men. The mean age at disease
onset in this group was 61 years (median 65 years, range 43-78 years) with a mean
disease duration of 11 months (median 10 months, range 2-30 months). Three of the
patients in this group were also in the long duration subgroup (duration of illness
being 29, 30 and 24 months) and three were under the age of 50 years at disease
onset. One patient, who had been diagnosed by cerebral biopsy, was alive at the time
of writing nearly two years into the illness. PRNP gene analysis (to exclude genetic
CJD) was performed in 12/27 (44%).
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Table 3.14: Presenting features in the "other focal onset" group (n=27)
NB. There may be more than one symptom at onset
Symptom No. of patients
Sensory disturbance 15 (56%)
Upper limb pain 1
Upper limb numbness 4
Upper limb parasthaesia 3
Lower limb pain 3
Lower limb numbness 1
Lower limb parasthaesia 3























This group also includes three unusual cases that developed a progressive
quadraparesis. They each complained of early and persistent sensory features:
burning dysasthaesia in the feet in one, pins and needles in the left upper and
lower limbs in the second and persistent, severe discomfort in the joints (for
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which no rheumatological cause was found) in the third. Unfortunately although
all three had a neuropathological examination (two an autopsy and one a brain
biopsy) tissue from the peripheral nervous system was not examined. A
diagnosis of sQD was only made in life in the case who underwent cerebral
biopsy.
The presence of specific clinical features throughout the illness in the focal onset
group is summarized in Table 3.15. When compared with the consecutively
selected Core group of sCJD patients (n=133) these patients were more likely to
have sensory symptoms (p=<0.001, chi squared test), involuntary movements
(p=0.01, chi squared test) and psychiatric symptoms (p=0.013, chi squared test).
Extrapyramidal signs were less common (p=0.002, chi squared test) as were
cerebellar signs (p=0.008, chi squared test). These results and those from the other
Atypical subgroups are summarized in Table 3.7.













Summaries of ages at onset and disease duration in the Atypical subgroups compared
with Core sCJD and total sCJD are to be found in Figures 3.5 and 3.6. Table 3.16
summarizes the male to female ratios amongst the subgroups.
Table 3.16: Male to female ratio in atypical subgroups
Male: female
Young cases (n=34) 16:18
Long duration cases (n=28) 13:15
Cerebellar onset cases (n=25) 17:8
Pure visual onset cases (n=19) 7:12
Other focal onset cases (n=27) 10:17
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Figure 3.5: Scatter plot showing age at onset in Core sCJD, total sCJD and
Atypical subgroups




Figure 3.6: Scatter plot showing duration of illness in core sCJD, total sCJD and
Atypical subgroups
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Differences between clinical features observed in the Atypical subgroups and
Core sCJD are summarized in Figure 3.7. The columns highlighted in red indicate
subgroups where there was a statistically significant difference (p<0.05) in the
prevalence of the symptom or sign when compared to the core sCJD cohort.
Columns filled with grey indicate subgroups where the clinical feature in
questionwill be present by definition e.g. visual symptoms in the pure visual
onset group).
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Figure 3.7: Clinical symptoms and signs in Atypical sCJD subgroups compared
with the core sCJD group
3.7a Percentage with myoclonus in sCJD subgroups
100









Core sCJD Young Long Cerebellar Visual Other focal
onset
(n=133) (n=33) (n=28) (n=25) (n=19) (n=26)
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Investigations in Atypical cases
The EEG in Atypical sCJD.
One hundred and five patients with Atypical features (89% of the total Atypical
group) had an EEG. Seventeen patients (16%) had an EEG that showed characteristic
periodic sharp wave complexes. In order to limit confusion from now on this shall be
referred to as a "positive" EEG (which equates to the criteria for a "typical" EEG used
in Appendix 2). The proportion of positive EEGs was highest in the pure visual onset
group (39%). This is an equivalent level to that witnessed in sCJD as a whole within
the UK surveillance system (where 416 out of the 485 pathologically proven cases
had an EEG and 162 of these were regarded as positive) (NCJDSU data). None of the
long duration cases that had an EEG (n=22) displayed a positive recording. The
distribution of these positive recordings amongst the subgroups is illustrated in
Figure 3.8. Compared with the Core group (where 35/104 (34%) of final EEG
recordings were positive) young cases, long duration cases and pure cerebellar onset
cases were significantly less likely to exhibit a positive EEG (p=0.018, p=<0.001 and
p=0.025 respectively, Fisher's exact test).
The mean age at onset within the positive EEG group was 63 years (range 43-78
years) compared with 57 years in the Atypical cases with a negative EEG (see Figure
3.9). A positive EEG was significantly associated with an older age at disease onset
(p=0.038, Wilcoxon rank sum test) amongst the clinically Atypical cases. Atypical
cases with a positive EEG had a mean duration of illness of 4 months (rangel-9
months) compared with amean duration of 17 months in the Atypical caseswith a
negative EEG. The distribution of disease duration in these Atypical cases with EEG
recordings is illustrated in Figure 3.10. A positive EEG was significantly associated
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with a shorter disease duration (p=<0.001, Wilcoxon rank sum test) amongst the
clinically atypical cases. Fifteen out of the 17 with a positive EEG had documented
myoclonus at the time of the recording (88 per cent). In two cases the clinical details
regarding the presence or absence ofmyoclonus were unclear. Fourteen out of 17
were bed bound at the time of the EEG (82 per cent) with only one patient clearly
documented as still being mobile. Codon 129 genotype was known in seven out of
the seventeen and all were MM (four MM1; three glycotype unknown). Figure 3.11
illustrates the timing of the EEG in terms of proportion of illness passed.
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Figure 3.8: Percentage of positive EEGs in sCJD compared with Atypical
subgroups
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Figure 3.9: Age at disease onset of Atypical sCJD cases with positive EEGs (n=17)
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Figure 3.10: Duration of illness in clinically Atypical cases with a) a positive EEG
(n=17) and b) a negative EEG (n=88)
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Figure 3.11: Duration of illness (|) and timing of EEG (♦) in a) Atypical sCJD with
positive EEG recordings (n=16) and b) Atypical sCJD with negative EEG
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CSF 14-3-3.
This was performed in 42 of the clinically Atypical patients (37%). In seven cases the
patient fell into more than one Atypical subgroup (hence 49 results in Table). CSF 14-
3-3 showed greatest sensitivity in the cerebellar and visual onset groups (at 83% and
75% respectively) and was less sensitive in the long duration group (at 50%). In sCJD
as a whole (i.e. all cases) the sensitivity of this test is approximately 95%34. Table 3.17
summarizes the results from each of the subgroups.
Table 3.17: Results of CSF 14-3-3 analysis in Atypical sCJD subgroups
Number tested and % of total tested in brackets




12 (71%) 5 (29%) 0
Long duration
(n=8)
4 (50%) 4 (50%) 0
Cerebellar 10 (83%) 2 (17%) 0
onset
(n=12)
Pure visual 3 (75%) 0 1 (25%)
onset
(n=4)
Other focal 5 (63%) 2 (25%) 1 (12%)
onset
(n=8)
Core sCJD 46 (79%) 4 (7%) 8 (14%)
(n=58)
Due to the fact that 14 % in the Core sCJD were rendered unsuitable for analysis a
comparison between positive and negative results in the subgroups and the Core
group was not performed.
Cerebral MRI.
MRI sans were available for review at the NCDJSU in 30 cases with Atypical clinical
features (some patients had more than one Atypical feature, hence the larger total
number of cases in Table 3.18). MRI scans from Atypical cases were compared with
scans from the sCJD Core groupwithout Atypical features, matched for scan date
within one year (as scan quality varied with the development of MRI as a technique).
There was no statistically significant difference (using a chi squared test) between the
proportion of patients with high signal in the basal ganglia in each Atypical
subgroup and Core sCJD.
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Table 3.18: Numbers of patients with basal ganglia high signal on MRI










Young 9 (56%) 7 (44%) 16
Long duration 4 (67%) 2 (33%) 6
Cerebellar onset 8 (80%) 2 (20%) 10
Pure visual onset 0 3 (100%) 3
Other focal onset 2 (22%) 7 (78%) 9
sCJD without
Atypical features*
18 (56%) 14 (44%) 32
* where scan dates were matched with the available scans from Atypical cases
The relationship between clinical parameters and high signal in the basal ganglia
on brain MRI.
Clincal features, age at disease onset and illness duration were noted for each of
the patients where MRI scans were reviewed. High signal in the caudate head
and the putamen of the basal ganglia was graded for each individual according
to a four point scale: 0=No signal change, l=normal level of signal change,
2=mildly increased signal, 3=moderately increased signal, 4=strongly increased
signal. There was no significant difference between the age at onset or the illness
duration in months between those with high signal in the basal ganglia (scoring 2
or more) and those without high signal in the basal ganglia (Wilcoxon rank sum
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test). There was no significant positive association between the presence of basal
ganglia high signal (grades 2,3 or 4) and any of the following clinical features
(recorded for each of the patients): myoclonus, cerebellar signs, involuntary
movements (other than myoclonus), extrapyramidal signs, sensory features or
pyramidal signs (analysis performed using chi-squared and Fisher's exact tests).
Codon 129 genotype and glycotype.
Table 3.19 and Figure 3.12 display the proportions ofMM, MV and VV genotypes
according to subgroups. Cases with a focal onset and a delayed dementia exhibited
approximately the same distribution of genotype as that seen in total sCJD. All of the
tested cases that presented with a pure visual onset had an MM genotype. In
cerebellar onset casesW was the most common genotype amongst those tested, in
young casesMM was the most common genotype whereas in long duration cases
there was an excess of patients with a MV genotype. Glycotype data was not
available in all of those with codon 129 genotype data and the available data is
summarized in Table 3.19.
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Table 3.19: Gentoype and glycotype analysis in tested Atypical cases
GLYCOTYPE
(numbers of patients)
Unknown 1 2A Total
YOUNG
MM 8 3 4 15 (52%)
MV 4 1 0 5 (17%)
VV 5 2 2 9 (31%)
LONG DURATION
MM 2 0 3 5 (29%)
MV 4 2 3 8* (47%)
VV 3 1 0 4 (24%)
CEREBELLAR
MM 1 1 0 2 (13.3%)
MV 2 1 3 5* (33.3%)
VV 1 1 7 8* (53.3%)
VISUAL
MM 6 7 0 13 (100%)
MV 0 0 0 0
VV 0 0 0 0
FOCAL ONSET
MM 5 4 0 9 (69%)
MV 1 1* 1* 2* (15.5%)
VV 1 0 1 2 (15.5%)
*
One patient exhibited both glycotype 1 and glycotype 2A
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Figure 3.12: Distribution of MM, MV and W genotypes in the general population,
sCJD as a whole, Core sCJD and Atypical subgroups
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When compared with the distribution of genotype observed in Core sCJD only
the long duration and the cerebellar onset cases exhibited a significantly different
variation in genotype distribution (p=0.009 and p=<0.001 respectively, Fisher's
exact test). Cerebellar onset cases exhibit more VV and MV genotypes than Core
sCJD cases. Long duration cases were more likely to have a MV genotype, with
less MM cases. More numbers are needed to understand any potential
significance of the MM genotype observed in all of the pure visual onset cases
tested (n=13).
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Referral to the NCJDSU in Atypical cases
Time from disease onset to notification to the NCJDSU.
The date of notification to the NCJDSU was known for each individual and the
number of days from disease onset to notification was calculated for all. This
calculation included those who were referred after death but they are considered in
more detail in the next section. The range of notification timings in days and the
mean for each subgroup (and Core sCJD) is displayed in Figure 3.13. With the
exception of cases presenting with a pure visual onset there was a significant delay
observed when comparing notification times between the Core group and other
subgroups (long cases p=<0.001, cerebellar onset cases p^O.OOl, young cases
p=<0.001, other focal onset cases p=<0.001, Wilcoxon ransksum test). Pure visual
onset cases were more likely to be referred earlier in the disease when compared
with the Core group (p=0.046, Wilcoxon ranksum test). Fifteen of the 19 pure visual
onset cases (79%) were referred initially to an ophthalmologist. Two cases with a
pure visual onset of disease had cataract extractions performed after symptom onset
and before the diagnosis of sCJD was made.
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Figure 3.13: Time from disease onset to NCJDSU notification in Core sCJD and
Atypical sCJD
(range of notification timing (minimum and maximum) indicated by the diamond, mean time to
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Applying the diagnostic criteria to Atypical cases.
Patients living for greater than two years did not meet the criteria for a case of sCJD
(see Table 1.10) because illness duration of greater than two years was an exclusion
criteria*. Eleven (33%) young cases did not meet the criteria for a case of sCJD. In
eight this was because the disease duration exceeded two years, in one because the
patient was not considered to have a "rapidly progressive" dementia, in one because
of a lack of neurological signs and in one because of a lack of clinical information. In
young, long duration and other focal onset cases there was a higher proportion who
*
If the EEG was negative, as it was in all of these cases
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did not meet the clinical criteria for a case when compared with Core sCJD (33%,
100% and 26% respectively versus 7% for Core sCJD with p=<0.001, p=<0.001 and
p=0.005 respectively (Fisher's exact test). Pure visual onset cases were most likely to
meet the case definition with over 95% being classified as Possible or Probable sCJD
(at a comparable level to that seen in Core sCJD). The proportion of cases meeting the
definitions for Definite, Probable and Possible sCJD are summarized in Figure 3.14.
In light of the finding that some of the focal onset sCJD cases may present with
isolated sensory or psychiatric features the case definition for vCJD (see
Appendix 1) was applied to the cases in whom these features were described at
onset (n=16). Five of these patients met the criteria for a Possible case of vCJD.
None met the criteria for a Probable case of vCJD. In the five "Possible vCJD"
cases the diagnosis of sCJD was considered more likely in four and vCJD
considered more likely in one case. Three of these cases were younger than 50
years of age.
Table 20 summarizes the significant differences observed in Atypical subgroups






Table 3.20a: Features associated with Atypical subgroups (young, long duration
and pure cerebellar onset) when compared with Core sCJD
Atypical Subgroup Feature significantly associated with
subgroup when compare to Core sCJD
Young cases • Less unsteadiness/ataxia at onset
• More personality/behaviour change at
onset
• More psychiatric symptoms &
involuntarymovements (other than
myoclonus) throughout the illness
• Less cerebellar or extrapyramidal
features throughout the illness
• Later notification to the NCJDSU
• Less likely to have a positive EEG
• Less likely to meet the criteria for a
Possible or Probable case in life
• Younger age
Long duration cases ® Personality/behavioural change and
depression more common at disease
onset
• Unsteadiness/ataxia less common at
onset
• More psychiatric features throughout
the illness
• Less extrapyramidal or cerebellar
features throughout the illness
• Less likely to have a positive EEG
• More MV andW genotype at codon
129 and less MM
• Later notification to the NCJDSU
• Notmeeting the criteria for a Possible
or Probable case
• Longer illness duration
Pure cerebellar onset cases • Younger age at onset but only one
younger than 50 years of age
• More visual disturbance, sensory
symptoms and psychiatric symptoms
throughout the illness
• Less likely to have a positive EEG
• Less MM and more MV andW
genotype at codon 129
• Later notification to the NCJDSU
130
Table 3.20b : Features associated with Atypical subgroups (visual and other focal
onset) when compared with Core sCJD
Atypical Subgroup Feature significantly associated with
subgroup when compared with Core sCJD
Pure visual onset • Shorter disease duration
• Less extrapyramidal and cerebellar
signs throughout the illness
• Early notification to the NCJDSU
• All tested cases had an MM genotype
Other focal onset cases • Younger age
• Longer illness duration
• More sensory and psychiatric
symptoms and involuntary
movements (other than myoclonus)
throughout the illness
• Less extrapyramidal and cerebellar
signs throughout the illness
• Later referral to the NCJDSU
• Less likely to meet the criteria for a
Possible or Probable case
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Summary of findings in Atypical cases
• Approximately one quarter of all patients with pathologically proven sCJD
possess one or more Atypical features according to the criteria used in this
study.
• Young cases are associated with symptoms of personality or behavioural
change at onset and more psychiatric symptoms and involuntary movements
during the illness that that observed In Core sCJD.
• Long duration cases are more likely to present with depression or
personality/behavioural change. The majority of long duration cases exhibit a
genuinely slower disease progression (only two were reported as losing the
ability to walk within one year).
• Ataxia is less commonly observed at onset in the young or those who live for
more than two years.
• Apart from in cases presenting with a pure cerebellar syndrome,
extrapyramidal signs and cerebellar signs are less commonly observed in
Atypical cases.
• Pure cerebellar onset cases complain ofmore sensory symptoms and visual
disturbance than Core sCJD cases. Psychiatric symptoms are also more
common in this group. There are more men than women presenting in this
way, at a ratio of 2.1 to 1.0, although numbers are small.
• Cases presenting with pure visual symptoms live for a shorter period and are
notified earlier to the NCJDSU than Core sCJD. In our series all tested pure
visual onset cases had a MM genotype at codon 129 of the prion protein gene.
• Sensory and psychiatric symptoms and involuntary movements (thoughout
the course of the illness) are associated with cases presenting with focal
symptoms (other than cerebellar or visual problems).
Patients with a focal onset tend to be younger and live for longer than those
the Core sCJD group.
Amongst Atypical cases a positive EEG is associated with an older age at
disease onset, a shorter disease duration and anMM genotype. With the
exception of pure visual onset cases, a positive EEG is less likely to be
observed in clinically Atypical cases.
There are no significant associations between patient age, disease duration,
Atypical subgroup, specified clinical features and the presence of basal
ganglia high signal on cerebral MRI in a group of 62 sCJD cases.
With the exception of pure visual onset cases, there is a significant delay
observed in the notification of Atypical cases to the NCJDSU.
Occasionally, cases with a pure visual onset of disease may undergo
needless ocular surgery
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Cases referred by neuropathologists after autopsy
Ninety one (19%) out of 485 pathologically proven cases of sCJD were not referred to
the NCJDSU whilst the patient was alive but were notified after a postmortem
examination had confirmed the diagnosis of sCJD.
These cases comprised of those in whom the diagnosis of CJD was not suspected at
all and cases in whom the diagnosis of CJD had been raised as a possibility. Twenty
six cases out of the 91 (29%) were not suspected to have CJD in life. In 65 unreferred
cases (71%) CJD was considered to a varying extent (ranging from one of a number of
suggested diagnoses to a clear clinical decision that sCJD was the most likely
diagnosis) but despite this a referral to the NCJDSU was not made. The age
distribution of all cases referred after autopsy (suspected and unsuspected) is shown
in Figure 3.16. Those referred after autopsy were older than the cases of sCJD in this
cohort referred before autopsy (n=393) (Wilcoxon ranksum test, p=0.005). The
distribution of illness duration in those referred before and after autopsy is
summarized in Figure 3.17. Cases referred after autopsy tended to be of longer
duration than those referred in life (p=0.044, Wilcoxon ranksum test).
Unsuspected cases of sCJD
Twenty six (5%) of total pathologically proven sCJD cases were not suspected to
have CJD whilst they were alive. The mean age at onset in this group was 70
years (median 68 years, range 44 to 94 years). Mean duration of illness in this
group was 15 months (median 7 months, range 2-74 months). Thirteen cases
were men, thirteen were women. In seven cases no alternative diagnosis was
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proposed and in five cases Alzheimer's disease was cited as either the most likely
diagnosis or as one of two potential diagnoses. A summary of the proposed
alternative diagnoses in these cases is given in Table 3.21. A summary of the
presenting features amongst unsuspected cases is found in Table 3.22. Presenting
features were comparable to those seen in sCJD (see Table 3.1) where the
diagnosis had been suspected before death.
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Table 3.21: Alternative diagnoses that were considered in unsuspected autopsy
proven sCJD cases
Final clinical diagnosis in unsuspected
group with neuropathologically proven
sCJD
Number of patients (n=26)








Squamous cell lung cancer 1
Motor neurone disease 1
Cerebral infarct &motor neurone 1
disease
Alcohol excess contributory 2
Ischaemic diabetes mellitus-related 1
cerebellar degeneration
Progressive supranuclear palsy 1
TOTAL 26
136
Table 3.22: Presenting symptoms in the unsuspected group
(more than one symptom may be present at onset)
Presenting symptom Unsuspected sCJD (n=26)
Memory loss, confusion, forgetfulness 10
or disorientation
Gait unsteadiness 8










Clinically "typical" unsuspected cases.
In five (19%) of these 26 unsuspected cases the clinical course was clearly
documented as a rapidly progressive dementia with myoclonus and a duration of
illness of less than six months. Only one of these patients with an apparently typical
course had been seen by a neurologist. Seven (27%) other unsuspected cases had a
rapidly progressive dementia with a duration of less than six months but the
presence of specific neurological signs was uncertain. Three of these seven patients
had been assessed by a neurologist. In total 12 (46%) of the clinically unsuspected
group had an illness duration of less than six months, with four having been assessed
by a neurologist. A summary of the number of cases referred after autopsy that were
assessed by a neurologist can be found in Figure 3.19.
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Atypical features in the unsuspected group.
When criteria for an Atypical case are applied to the unsuspected cases, 10 (38%)
possessed Atypical features. These Atypical features were a long duration of illness
(>two years) in six, a young age at onset (<50 years) in two, presentation with a pure
cerebellar syndrome in one and a focal onset (other than with cerebellar or visual
symptoms) in three. Two patients were both young and had a long duration of
illness. Both were women (aged 44 and 48 years with disease durations of 60 months
and 37 months respectively) and the clinical diagnosis in life was that of Alzheimer's
disease. The two patients with the longest duration of illness in the total sQD group
in this study (n=485) were unsuspected cases (with durations of illness of 60 and 74
months).
In addition to defined Atypical features the following characteristics were noted in
six other patients, which caused diagnostic confusion:
1 An Electromyelogram (EMG) reported as showing "large motor unit
potentials in all muscles sampled with fasciculation potentials....thismust be motor
neurone disease" in one case.
2 A duration of illness of 23 months in one patient associated with a slower than
expected progression of dementia and physical impairment.
3 The coexistence of sCJD and Alzheimer's disease at postmortem (clinically at
least three years of cognitive decline followed by a rapid deterioration lasting three
months) in one case.
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4 A diagnosis six months prior to disease onset of an inoperable squamous cell
lung cancer.
5 Alcoholism (in two patients)
When compared with Core sQD long duration cases were found to be more likely to
be referred after autopsy (p=0.05, Fisher's exact test). Although there were variations
in the number referred pre and post autopsy between Atypical subgroups and Core
sCJD (see Figure 3.18) these did not reach statistical significance. Twelve (46%) of the
unsuspected cases were assessed by a neurologist. One other case was discussed over
the telephone with a neurologist but was not seen.
Figure 3.15 displays the proportion of cases with Atypical features amongst those
referred both before and after autopsy. As the graphs display the proportion of
Atypical cases is very similar in both groups.
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Figure 3.15: Proportion of cases with Atypical features in those referred before
and those referred after autopsy
a: Proportion of Atypical cases amongst sCJD referred after autopsy (n=91)
□ Atypical sCJD
Other sCJD




Applying the case definition to unsuspected cases.
Classifying the patients in retrospect according to the case definition for sporadic
CJD was problematic, as many of the clinical features commonly observed in CJD
had not been documented (as either present or absent). However, none of the
patients met the criteria for a Probable case (due to the lack of supportive
investigations being performed). Thirteen met the criteria for a Possible case. The
remaining 13 did not meet the definition for a case of sCJD due either to long
duration (in six cases), documented lack of physical signs (in five cases) or an
absence of reliable clinical data (in two)
The importance of accurate premortem diagnosis of CJD is again highlighted by the
occurrence, in one of the unsuspected cases, of corneal donation after death for
transplantation into two other individuals (a reported method of onward
transmission of the disease producing agent).
Clinically suspected but unreferred cases
Sixty five (71%) of the 91 unreferred cases were not notified to the NCJDSU in life
despite the diagnosis of CJD being raised. In 30 (46%) of these suspected cases review
of the case-notes revealed that CJD was considered the most likely clinical diagnosis.
In 25 (38%) the diagnosis of CJD was mentioned at least once but often in the context
of other potential diagnoses and was not highlighted as the most likely diagnosis. In
ten cases there was not enough clinical information to be sure of the degree of
diagnostic certainty. Forty four of these suspected cases (68%) underwent assessment
by a neurologist. The involvement of neurologists in these unreferred cases is
summarized in Figure 3.19. The difference between the proportion of unsuspected
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and suspected cases seen by neurologists (46% and 68%) is not significant when
Fisher's exact test is applied (p=0.09). The place of residence of each unsuspected case
was plotted on a map of the United Kingdom (see Figure 3.21) with the aim of
identifying if the unreferred cases were originating from the same areas. Unreferred
cases show a wide distribution throughout the United Kingdom with a higher
number of cases in some of the larger cities (as would be expected with a greater
population density).
Investigations in cases referred only after autopsy
Of the 91 cases referred to the NCJDSU after autopsy, 57 (63%) were documented
as having had an EEG recording. Of these, seven (12%) showed an appearance
considered positive for sCJD upon review by the NCJDSU. All of these seven
were thought to have sCJD by the clinical team involved but the NCJDSU was
only contacted in one case. In this case CSF was tested for 14-3-3 but the result
was negative and the patient was not referred on for a clinical opinion. Only
three cases had CSF examined for 14-3-3 and in all three it was negative. Cases
with positive CSF 14-3-3 would become classified as formal "referrals" whilst
alive as there is close communication between the CSF laboratory staff and the
clinicians at the NCJDSU. It is less clear how many of these patients underwent
brain MR imaging and the scans were infrequently available for review by
NCJDSU staff.
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Distribution by year of all cases referred after autopsy
There was a variation year on year of the number of cases not referred in life to the
NCJDSU. Figure 3.20 demonstrates the number of pathologically proven cases of
sCJD identified per year with the proportion which were only notified after autopsy.
It demonstrates that the overall number of cases referred to the NCDJSU until the
end of 2002 is showing an increasing trend which is not reflected in the number of
cases referred after autopsy. Figure 3.22 breaks down these unreferred cases into
those who were suspected and those who were unsuspected, by year of notification.
In 1997 both the greatest number of overall post-mortem examinations and the
greatest number of cases referred after autopsy occurred. There has been a decline in
autopsy rates for CJD recently, as Figure 3.23 demonstrates.
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Figure 3.18: Percentage of cases in atypical subgroups referred after postmortem
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Figure 3.20: Number of cases referred after autopsy over time compared with total














Figure 3.21: Map showing places of residence of cases of sCJD only notified after
autopsy (n=91)
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Figure 3.22: Number of cases notified after autopsy that were suspected and
unsuspected 1990-2002
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Figure 3.23: Percentage of referrals of suspected CJD coming to autopsy in the
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Summary of findings in cases referred to the NCJDSU after autopsy
• 19% of all pathologically proven sCJD cases were only notified to the NCJDSU
after autopsy.
• In just under one third of these cases the diagnosis of CJD was not suspected
in life.
• Cases referred after autopsy were significantly older than those referred
before autopsy.
• Disease duration was significantly longer in the group referred after autopsy
compared with sCJD cases referred before autopsy.
• 38% of unsuspected cases showed Atypical features according to our
definition
• Just less than one half of the unsuspected cases appeared to have a typical
clinical course that went unrecognised.
• Neurologists were involved in 46% of unsuspected cases and 68% of
suspected cases that were not notified in life.
• There were no clear geographical areas that corresponded with cases
unreferred in life, although numbers were small.
• There are not an increasing number of cases being referred after autopsy,
which may in part reflect the decreasing postmortem rates seen in the UK.
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Possible sCJD
Between 1990 and the end of 2002, 59 referrals have been made to the NCJDSU of
patients who were finally classified as Possible sCJD. The diagnosis in these
patients remains uncertain and they are not included in the national statistics for
CJD cases.
According to the case definition for sQD (see Table 1.10) for a patient to be a Possible
case they must possess a rapidly progressive dementia plus two of the following:
extrapyramidal/ pyramidal signs; akinetic mutism; cerebellar/visual problems or
myoclonus with a duration of illness of less than two years. To be classified as a
Probable case these criteria need to be met along with a positive supportive
investigation (CSF 14-3-3 or EEG).
Distribution ofPossible cases overtime
There has been a general increase over time in the number of Definite, Probable and
Possible sQD cases referred to the NCJDSU (apart from a dip in referral numbers in
1995 and 1996) (see Figures 3.24a and 3.24b). The overall proportion of Probable cases
has risen over time which may reflect the decreasing trend for autopsies to be
performed (see Figure 3.23). The proportion of Possible cases has fluctuated over the
12 years of surveillance (Figure 3.24).
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Figure 3.24b: Overall number of Definite, Probable and Possible sCJD referrals
1990-2002











Figure 3.25: Percentage of total Definite, Probable and Possible sCJD finally










Clinical features in Possible cases
33 (56%) of the Possible cases were women. The mean age at onset in this group was
73 years (median 68 years, range 37-89 years). The mean duration of illness in the
Possible cases was 5 months (median 4 months, range 2-13 months). Sixteen (31%)
had a disease duration of three months or less associated with myoclonus. In these
cases the clinical picture strongly resembled that seen in sCJD but all lacked a
positive supportive investigation.
Investigations in Possible cases
A positive investigation is required for a Possible case to be classified as
Probable. The absence of a positive investigation may either occur because the
investigation has not been performed or because the investigation was negative.
Taking sCJD as a whole, CSF 14-3-3 is negative in about five per cent of total
sCJD. The EEG needs often to be repeated for a positive result to be obtained and
a negative result may indicate that the test has not been employed to its best
advantage.
Six (10%) of the 59 patients with a classification of Possible CJD had CSF 14-3-3
analysis performed. Three of these were negative and three were bloodstained
(rendering them unsuitable for analysis). The reasons why CSF 14-3-3 was not
performed in the remaining 53 patients are summarized below:
n
Patient's illness predated the availability of the test
Lumbar puncture performed but 14-3-3 not requested





Family did not wish for the test to be performed





EEG was performed in 51 out of 59 (86%) and none showed the characteristic
periodic sharp wave complexes. In 27 (46%) of these only one EEG was performed.
The timing of the EEGs (where known) in terms of proportion of illness passed is
expressed in Figure 3.26. This shows that only 13 patients with a diagnosis of
Possible sCJD (22%) had an EEG recording in the final month of their illness. The
number of EEG recordings per patient is shown in Figure 3.27. Eighty two per cent
had one or two EEG recordings only.
Nine patients with a diagnosis of Possible sCJD (15%) had an MRI scan which was
available for review by an experienced neuroradiologist at the NCJDSU. Three
showed definite high signal in the basal ganglia and one showed basal ganglia high
signal "probably consistent with sCJD but not typical". The remaining five scans
showed vascular disease in three/ high signal in the right frontal area of unknown
significance in one and a normal examination in one.
The codon 129 genotype was only known in eight cases (14%). Five were MM, two
were MV and one was VV. In 27 cases (48%) a referral was made and the patient was
assessed whilst alive by a NCJDSU doctor. In 24 cases (41%) the patient was not
referred to the NCJDSU until after death. Five patients (8%) were referred but not
seen before death and in three cases it is unsure when a patient was referred to the
NCJDSU (but they were not seen in life).
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Figure 3.26: Timing of final EEG recording (♦) as a proportion of the total illness
passed in Possible sCJD (all these EEGs were negative)


















Figure 3.27: Number of EEGs performed per patient in Possible sCJD
(51 patients)
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Summary of findings in Possible cases
• 59 cases of suspected sCJD referred to the NCJDSU from 1990-2002 have
remained as Possible sCJD only. This equates to an average of 4.9 cases per
year
• 16 (23%) of these cases had a clinical course that was strongly suggestive of
sCJD (i.e. duration of illness three months or less with myoclonus)
• Many cases were not fully investigated
• The NCJDSU was involved in just over half of the cases whilst the patient was
alive.
• If the MRI scan were to be included in the diagnostic criteria with the same
weighting as the EEG or CSF 14-3-3 it would only allow three (out of 59)
further patients to be reclassified as Probable, but many scans were not
available for review.
• Following on from the introduction of CSF 14-3-3 the number of cases




Approximately eleven per cent of referrals made to the NCJDSU with suspected CJD
have an alternative diagnosis proven at autopsy *. A summary of the alternative
diagnoses in the 182 cases referred to the NCJDSU (1990-2002) with initially
suspected CJD (who subsequently had an autopsy confirming an alternative
diagnosis) is found in Table 3.23. The three most common alternative diagnoses are
Alzheimer's disease (AD) (37% of pathologically proven not CJD cases), Lewy body
dementia (LBD)(13%) and cerebrovascular disease(CVD)/ multi infarct dementia
(9%).
Clinically selected pathologically proven non sCJD
A previously undiagnosed case ofsCJD.
A case file review of the clinical features and investigation results in the 45 non cases
referred with suspected sCJD who were assessed by a NCJDSU doctor whilst alive
was performed. One of the patients displayed many of the features considered
typical for sCJD. He was an 84 year old man who developed a rapidly progressive
dementia associated with ataxia and myoclonus. After a period of just over two
months from the symptom onset he was akinetic and mute. Death ensued by three
months. An EEG recording taken in the final month of the illness showed an
appearance considered positive or "typical" for sCJD (reviewed blinded to diagnosis
*
Approximately 1650 cases referred to the NCJDSU by the end of 2002 ofwhich 182 had other diagnoses
proven at autopsy
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at the NCJDSU according to the criteria outlined in Appendix 2). He died prior to the
advent of CSF 14-3-3 as a diagnostic test but did meet the criteria for a Probable case
of sCJD. The original pathological diagnosis was Alzheimer's disease with
angiopathy and infarcts.
In light of the clinical features, which convincingly supported a diagnosis of
sCJD despite neuropathology to the contrary, a review of the autopsy findings
was requested. Further histological examination was carried out using Paraffin
Embedding Tissue (PET) blotting** which detected PrP deposition in the temporal
lobes. This technique is more sensitive than conventional immunocytochemsitry
as it can detect smaller amounts of PrPSc. This was considered to be an unusual
finding indicative of early Prion disease (personal communication, Professor
James Ironside). In view of the clinical features it was taken to represent a dual
pathology of Alzheimer's disease and sCJD.
Following on from this the clinical features of the remaining 44 clinically selected non
cases were reviewed to see if neuropathological review would be warranted in
further cases. Two male patients died with an autopsy diagnosis of Alzheimer's
disease (in one case with coexisting cerebrovascular disease) where myoclonus was
clearly documented and the duration of illness was less than six months. In both
cases there had been a rapidly progressive dementia and in one case the patient had
become akinetic and mute after three months. EEG recordings were not considered
typical for sCJD, CSF 14-3-3 had not been performed and they had both met the
clinical criteria for Possible sCJD. In these cases, however, an extensive review of the
"
This technique differs from routine immunocytochemistry in that the paraffin tissue is embedded onto a
nitrocellulose membrane. This can then be treated with lower concentration ofProteinase K than is
158
neuropathology with further immunocytochemistry and PET blotting failed to
demonstrate any evidence of sCJD.
Alternative diagnoses in clinically selected non cases.
In the 44 clinically selected non cases with suspect sCJD the most common
alternative diagnosis was Alzheimer's disease in 20 (45%)***. Lewy Body Dementia
was proven in five (11%) and cerebrovascular disease in four (9%). These cases
represented those where the patient had been assessed in life by a NCJDSU
neurologist. Neoplastic or paraneoplastic disease was the underlying diagnosis in six
cases (14%). Despite an autopsy the diagnosis remained unknown in three cases.
These findings are summarized in Table 3.24. The most common reasons for referral
to the NCJDSU include a "rapid deterioration" of cognitive function (cited in 35
patients (80%)) and the presence of a dementia with added features (especially
myoclonus) (see Table 3.25).
Illness duration in clinically selected non cases.
The mean duration of illness in the not sCJD group (n=44) was 26 months (range 4-
108) (duration known in 43/44). Of those in the clinically suspected sCJD group ten
had a duration of illness of six months or less. The diagnoses in this group were as
follows:
Neoplastic/paraneoplastic disorders 5
normally used in immunocytochemistry. This is used to destroy the normal PrP (PrPc) leaving the
abnormal form of PrP (PrPSc) which is then detected using antibodies.
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Alzheimer's disease 3
(including one patientwith a diagnosis of AD and cerebrovascular disease)
Cerebrovascular disease 1
Diagnosis uncertain 1
A comparison between disease duration in non cases and in sQD can be seen in
Figure 3.30. There were not any non cases with a disease duration of three months or
less.
Clinical symptoms and signs in clinically selected non cases.
Myoclonus was reported in 28 cases with following diagnoses:
Alzheimer's disease (AD) 14
AD & CVD 2
Cerebrovascular disease (CVD) 3
Lewy body dementia 3
Encephalitis 2
Progressive supranuclear palsy 1
Chronic granulomatous encephalopathy 1
Multifocal calcifying leukoencephalopathy 1
Diagnosis uncertain 1
The presence or absence of specific clinical features was noted in all of the clinically-
selected non cases, which gives a further indication of possible reasons why sCJD
was suspected (see Table 3.26).
***
This figure includes three cases with both Alzheimer's disease and Cerebrovascular disease (CVD)
which are not included in the total figure for CVD
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Investigations in non cases
Thirty four of the 44 clinically selected non cases (77%) had an EEG recording. Upon
review in the NCDJSU none of the recordings were sufficiently characteristic to be
considered positive for sQD (i.e. typical according to NCJDSU criteria outlined in
Appendix 2). CSF 14-3-3 was tested in 15 (34%) and was positive in five cases, all
with a final diagnosis of paraneoplastic syndrome. Cerebral MRI results were
recorded in 18 (41%): ten were reported as normal, three were reported as showing
atrophy only, three were reported as showing white matter ischaemic change only
and two had both atrophy and ischaemic changes.
Cases with a final diagnosis ofAlzheimer's disease
Alzheimer's disease is the most common alternative diagnosis in both clinically
selected and unselected cases referred as suspect sCJD. The group of 20 patients in
the clinically selected group with a final diagnosis of AD were analyzed separately to
identify common factors.
The mean age at onset of these cases was 64 years (range 33-82 years, median 64
years). The mean duration of illness in this group was 42 months (range 6-108
months, median 33.5 years). Presenting symptoms were most commonly those of
cognitive decline, seen in ten of the patients (50%). Other features at presentation
were anxiety (n=3), difficulty mobilising (n=2) with headache, dizziness, loss of
consciousness, paranoia, withdrawal, obsessive thoughts and weight loss each
reported in one patient.
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Myoclonus was seen in 16 (80%), pyramidal signs in 14 (70%) and psychiatric
symptoms in 13 (65%). Other less common features included other involuntary
movements (seen in 11 (55%)), cerebellar signs (seen in 6 (30%)), extrapyramidal
features (seen in 4 (20%)), sensory disturbance (seen in 3 (15%)) and visual
disturbance (reported in 2 (10%)).
The last patient to be referred to the NCJDSU and seen with a final diagnosis of AD
was visited in 1998 and most of these referrals (n=18) occurred within the first five
years of surveillance (i.e. pre-1995).
162
Table 3.23: Diagnoses in autopsy proven non cases, 1990-2002*
Diagnosis Number of cases (n=182)
Alzheimer's disease (AD) 54
AD + Cerebrovascular disease (CVD) 4
AD + Lewy body dementia (LBD) 7
AD with amyloid angiopathy 1
AD with congophilic angiopathy 1
Lewy body dementia 23
LBD + CVD 1
Cerebrovascular disease 15
Multi infarct encephalopathy 1






Primary brain tumour 2
Paraneoplastic cerebellar syndrome 2
Paraneoplastic syndrome with perivascular 1
inflammation





Subacute necrotising encephalitis 1
Non-specific encephalopathic features in 1
the basal ganglia and thalamus
Post viral encephalitis/Landau Kleffner 1
Syndrome
Herpes simplex encephalitis 1
Hypoxic damage 3
Progressive Multifocal Leukoencephalopathy 3
Progressive Supranuclear Palsy 2




*Plus one of each:
Multi system atrophy, Hashimoto's disease, multifocal calcifying leucoencephalopathy, Multi
system degeneration, amyloid angiopathy, widespread oedema and gliosis, corticostriatal nigral
degeneration, multiple sclerosis, Wilson's disease, chronic granulomatous encephalopathy,
Hepatic encephalopathy, Huntington's chorea.
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Table 3.24: Neuropathological diagnoses in 44 clinically selected non- sCJD cases
Diagnosis Suspected sCJD (n=44)
Alzheimer's disease (AD) 17
AD + cerebrovascular disease 3
CVD 4
Lewy body dementia 5











Figure 3.27: Pie chart displaying the proportion of clinically-selected non cases












Table 3.25: Reasons cited as to why sCJD was suspected in non cases
(n=44)
Reason why sCJD suspected Number of patients (% in brackets)
"Rapidly progressive dementia" 35 (80%)
Myoclonus 28 (64%)
Dementia plus cerebellar features 6 (14%)
Dementia plus 4 (9%)
pyramidal/extrapyramidal signs
CSF 14-3-3 positive 5 (11%)
EEG considered positive 7 (16%)
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Figure 3.29: Scatter plot showing duration of illness in clinically-selected non
cases (n=44) and total sCJD
Non cases
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Total sCJD
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Table 3.26: Clinical features observed in clinically-selected non cases (n=44)











Summary of findings in non cases
• The most common alternative diagnosis in non CJD cases referred as suspect
CJD is that of Alzheimer's disease.
• Rapidity of cognitive decline and myoclonus are the most common reasons for
a non CJD case to be referred as suspect sCJD.
• Most non cases have a longer duration of illness than that commonly seen in
sCJD.
• In those with a duration of illness of less than six months the most common
diagnosis is paraneoplastic/neoplastic disease.
• The typical phenotype of sCJD (short duration with myoclonus and a
characteristic EEG) is sufficiently distinctive to request neuropathological




This study has provided insights into the clinical manifestations of a rare
neurodegenerative condition of uncertain cause. By describing the patterns of
disease observed it aims to improve clinical diagnosis in the future. A
comprehensive recognition of cases allows for more complete study of the
disorder and of potential aetiological factors.
The study population and the documentation of symptoms and
signs
This study involved only cases of sCJD that had been neuropathologically confirmed.
Although this ensures complete accuracy in terms of the diagnosis there are potential
biases involved. Cases of sCJD may be more likely to undergo an autopsy or brain
biopsy if they are clinically unusual or the diagnosis in life is uncertain. Younger
patients may be over represented, as autopsies in the elderly are less common*.
This study relies on clinical data collected by several different observers. Since the
foundation of the surveillance unit in 1990, relatives have been interviewed and
patients examined by 11 observers, each an NCJDSU consultant neurologist or
research neurology registrar (with each research registrar recording data for a period
of approximately two years). Efforts have been made to standardize the information
gathered by the use of two proformas for the recording of clinical signs (one pre-
1997, one introduced in 1997). The latter proforma allows for greater uniformity of
data as symptoms and signs are specifically recorded along with their date of onset
*
As recorded by the Office of National Statistics for England and Wales
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(Appendix 3). The earlier proforma does provide an outline for the recording of
clinical details although it is less structured. The use of these proformas is likely to
minimize variations in the quality of the data recorded for each patient. It would not,
however, completely dispel the inevitable variation in interpretations of clinical
symptoms and signs by each observer of the patient's clinical state. However,
continuity was provided through individual case discussion with one of the two
members of consultant staff (one of whom had worked at the NCJDSU since 1990
and the other since 1996).
Emphasis has been placed on the presence or absence of physical signs. If a clinical
sign has not been recorded in the medical notes or observed by the visiting NCJDSU
doctor it cannot be taken to mean that it was definitely never present. Often, after a
diagnosis of CJD has been given, the emphasis turns toward palliative care and the
patient may not be examined neurologically again. If for example, myoclonus only
develops at this late stage in the illness it may never have been recorded as present.
In this study, for practical purposes, if a clinical symptom or sign has not been
recorded then it is regarded as absent because this reflects the realities of clinical
practice. Therefore "absent", "not sure" and "unable to ascertain" were recorded
together. It is possible that some of the "absent" or "not sure" responses may have
been recorded in patients who did actually have the clinical sign in question but in
whom it had not been elicited at the time of documentation. This may lead to an
under representation of certain signs. This effect should be equal across subgroups. It
could be argued that those in whom the diagnosis is uncertain are more likely to be
examined repeatedly therefore increasing the accuracy of detection of clinical signs in
more unusual cases. On the other hand, a more certain diagnosis may lead clinicians
to elicit signs typical of the illness.
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Classification of extrapyramidal signs may cause particular problems, as the wide
range of prevalence in different studies demonstrates (Table 1.3). Parkinsonism is
difficult to elicit in patients with sCJD as many cannot speak, write or walk.
Increased tone in the limbs may take the form of spasticity rigidity or "gegenhalten"
paratonic rigidity. The categorising of gegenhalten rigidity in the limbs (as either
pyramidal, extrapyramidal or other) has varied in previous studies and in also in
material produced from the NCJDSU88 and could therefore be thought of as largely
unreliable. In this study extrapyramidal signs are recorded as being present if the
observer specifies "extrapyramidal signs /Parkinsonism present" or if bradykinesia,
resting tremor or rigidity (not gegenhalten) are mentioned. Gegenhalten rigidity has
been considered separately as it is generally thought to be indicative of frontal lobe
disease208. The features observed in this study are compared with those seen in other
studies (Table 3.4). The presence and absence of certain symptoms may depend on
whether the relatives of the patient concerned were specifically asked about their
presence or absence. The use of the standardised proforma would be expected to
minimise error caused by the failure to ask as clear prompts are used. The consultant
staff at the NCJDSU have had consistent and uniform views on these issues since
1990 (personal communication, Richard Knight). This study is likely to be more
accurate than many previous studies looking at clinical features as most of the
patients here were assessed in life by a surveillance neurologist. Retrospectively
collected data from varied sources is fraught with bias and casts doubt on the
validity of some of the earlier work.
The date and nature of disease onset may be difficult to ascertain. Onset is important
as it provides information about disease duration and allows an assessment of early
symptoms and signs. This is crucial in identifying Atypical cases according to our
criteria. Information about disease onset aids subsequent work on pathogenesis and
171
susceptibility to disease of certain individuals. Often a NCJDSU doctor is able to visit
the family and time, often lacking in the busy schedule of the ward doctor, can be
taken to elicit a detailed history. The prospective gathering of information in this
manner is likely to increase the accuracy of the clinical history obtained. Clinical
information varies depending on whether the patient has close family or friends who
have observed the early stages of the illness. If a family is visited after the patient has
died the information received may not be as accurate as time will have elapsed.
Conversely, it could be, however, that reflection by family members may improve
accuracy as regards disease onset. They may recall early symptoms that initially were
not thought to be relevant. Sometime the distress of family members may lead to
difficulties in spending time over obtaining a detailed history and this may be aided
somewhat by the passage of time. Obtaining a history after the death of the patient,
therefore, may not have a uniform affect on the quality of information obtained.
The figure obtained in this study of 31% presenting with cognitive decline is
comparable to that seen in other studies (see Table 3.2). Occasionally there have been
significant difficulties in establishing the disease onset, for example if previous
alcohol abuse had been a problem or if there was co morbidity in the form of
psychiatric disease. These difficulties were experienced in the minority and because
of the dramatic decline often witnessed it was frequently possible to get a clear
history of the very first symptom from the relatives. Often clinicians call upon the
NCJDSU for an opinion regarding an unusual patient and a comprehensive
knowledge of presenting features allows for a more informed response in questions
related to the early stages of the disease.
A previous study has examined cases of sCJD which presented with a "stroke-like"
onset. This was not a common scenario at presentation in this study and when a
172
mistaken diagnosis of stroke did occur it was often soon corrected when a more
detailed history was taken (e.g. of progression after the initial event). That is to say,
the figures presented may have been an artefact of inaccurate history taking.
In order to identify cases for this study the author reviewed the complete NCJDSU
archive of pathologically proven cases on two occasions to identify patients who met
the criteria for study. The use of one observer eliminated the problem of observer
variability in selection and repeating the procedure minimised any chance that
information had been missed.
Atypical cases
What is the value in defining and studying them?
Clinical heterogeneity in sCJD has long been recognised64'65-'69;125. This study has
sought to clarify the extent of this variation and identify cases that cause
particular diagnostic problems. Clear distinctions made by definitions of "an
Atypical case" may be somewhat misleading. Definitions rely on fixed
boundaries when in reality what exists is a clinical spectrum of disease. In long
duration cases for example a patientwith an illness duration of 24 months is
Atypical (according to the definition used in this study) whereas a patient with a
disease duration of 23 months is not. There are therefore limitations in the
process of attempting to define Atypical and some unusual cases may fall
outside of the boundaries of a definition. Despite this, defining Atypical groups
does allow for the identification of many cases at the "end" of the phenotypic
spectrum that are likely to add to our understanding of the variation which exists
in disease phenotype. With about one quarter of all pathologically proven cases
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of sCJD meeting the definition of Atypical used here it is clear that clinical
heterogeneity is not insignificant. It follows that if too rigid a view of the clinical
picture in CJD is adhered to cases are likely to be missed. The description of the
full spectrum of disease in sCJD is important in improving the accuracy of
disease surveillance by enhancing case recognition. An understanding of the
variety of clinical presentations may increase the accuracy of early diagnosis.
Accurate diagnosis of CJD is important in counselling families and providing
appropriate care for patients. It allows for a prediction of disease trends and an
assessment of geographical distribution of cases. In the past, where unusual
cases have caused diagnostic difficulties, brain biopsies or other invasive
procedures may have been performed without adequate safety precautions,
carrying with them the inherent risks of onward transmission of the infective
agent.
An appreciation of the spectrum of clinical features within sQD will allow for
assessments of any change in the phenotype over time. This is particularly
important if vCJD cases with a MV or VV genotype at codon 129 are to emerge.
A clear description of the phenotypic variation in sCJD in the UK would allow
for a comparative study with other countries where a surveillance system exists
and thus to identify phenotypic variation with different environments.
Observed phenotypic variation in sCJD
Correlations between age9;65, duration of illness64'65 and clinical features have already
been highlighted in previous studies. This work builds on those observations by
studying subgroups defined by the following characteristics from a large cohort:
Duration of illness of greater than two years
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Age less than 50 years at disease onset
Onset with visual symptoms in isolation for at least the first two weeks of the illness
Onset with cerebellar features in the absence of cognitive decline for at least the first
month of the illness
Onset with other focal features (and no documented cognitive decline for at least the
first month)
Relatively distinct features found in each of the Atypical subgroups studied are
shown in Table 3.20a and 3.20b. These should aid in the recognition of thesemore
unusual cases in the future.
Why is phenotypic variation observed in sCJD?
It remains somewhat unexplained why differences in clinical phenotype should
occur. Certainly there seems to be a relationship with genotype at codon 129 of the
PRNP gene which has been highlighted by several studies. The current study has
described relatively distinct characteristics of subgroups of sCJD. Although there
does appear to be a relationship with differing genotypes in some of these groups it
is only the visual onset group that correlates fully with one genotype (MM). It should
be stressed, however, that numbers did not reach statistical significance when
compared with the distribution of genotype observed in the core group. Genotype
and prion strain influence the pathological distribution of abnormal prion protein87
and some of the focal features at onset are likely to relate to prion distribution in
focal areas. In the current study, prion strain data was incomplete and has not been
discussed further because of this limitation.
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In addition, it is possible that there may be some hitherto unidentified environmental
factor that influences phenotype. Work looking at the geographical distribution of
atypical cases has not been performed. An interesting starting point to examine this
further may be to compare the UK data on phenotype with that seen in other
European countries. Epidemiological data including occupation, places of residence
and previous medical history is collected for each case and this couldbe examined
further to see if patterns emerge within subgroups. So far, however, work looking at
causes of QD from this data has not yielded consistent risk factors and any possible
associations with different phenotypes remain purely speculative. The route of
acquisition influences the clinical picture in iatrogenic QD and it remains possible
that, if sQD is acquired from an external source (which in itself is controversial),
routes of infection may influence phenotype.
The genotype in the young may vary because of the way that the young brain
responds differently to abnormal prion protein compared with the ageing brain. The
prominent early psychiatric features (also seen in vQD) may partly reflect the
tendency to detect subtle early symptoms in the young that may be overlooked in the
elderly. There may be a greater capacity to compensate for diseased regions in the
younger brain explaining in part the known association with longer disease duration
observed in the young.
It should be acknowledged that genetic QD was not excluded in all cases therefore
raising the possibility, albeit unlikely, of genetic QD. This has previously been
described as causing a longer illness duration in younger patients, at times with
prominent cerebellar features at onset.
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Young cases.
These cases receive particular attention because dementia in the young is so
unusual and devastating. In addition, because of the age of these patients vQD is
more often considered. For many in this group the duration of their disease is
considerably longer than that typically associated with sCJD and in nine of the 34
identified cases it exceeded two years. Reasons for the association between a
young age at onset and a longer duration of illness have been commented on in
the introduction to this thesis. These include the detection of subtle early
symptoms in the young (that may have been attributed to the processes of ageing
in the elderly), the tendency to use artificial feeding more often in the young that
may prolong life and the fact that the elderly often have other medical problems
that may hasten a decline.
Psychiatric features are more commonly associated with young cases than with a
comparison group of Core sCJD and may raise the clinical possibility of vCJD 209. A
higher incidence of psychiatric symptoms in the young may partially reflect the
tendency to notice more subtle symptoms in young people and also the fact that
many of the younger patients were living with a spouse who would be likely to
detect disorders of mood or affect compared with the older patients where a higher
proportion may be widowed or living alone. Any features more commonly noted in
the young could be due to a closer observation in this age group, including the
finding that involuntary movements were more common. Both psychiatric features
and involuntary movements are prominent in vCJD (predominantly a disease of the
young) and the findings in this study may reflect how the younger brain responds to
prion disease. This study has shown that vCJD was considered in some of the young
cases but only exceptionally was it the preferred diagnosis. At times where there is
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clinical confusion, a brain MRI (looking for the "pulvinar sign") or a tonsil biopsy (to
detect PrP^) are useful procedures in distinguishing sCJD and vQD as both are
sensitive and specific for vCJD. The MRI has the advantage of being non-invasive,
although if there is no pulvinar hyperintensity the tonsil biopsy is a useful tool.
Cerebellar features are less commonly observed at onset or throughout the illness in
young cases when compared with Core sCJD. The fact that young cases are likely to
( be closely observed makes this unlikely to be due to under ascertainment of clinical
features. None of the cases that presented with virtually isolated cerebellar features
were aged below fifty years at disease onset but they were as a group significantly
younger than the mean age observed in the Core group of sCJD patients. Previous
studies examining cerebellar pathology in sCJD have demonstrated that abnormal
PrP deposits are observed in clusters that appear to be distributed along anatomical
pathways210 and that the codon 129 genotype affects the accumulation of PrPSc in the
cerebellum211. Valine homozygosity is more commonly associated with cerebellar
features and is also associated with a younger age at disease onset which appears to
be reflected to some extent in the cerebellar onset cases identified here. There is no
obvious explanation, however, for the lower incidence of cerebellar features
observed in the young cases of sCJD or the younger than average age observed in the
group presenting with virtually isolated cerebellar features.
CSF 14-3-3 was the most sensitive investigation in young cases, with just over 70% of
those tested (n=17) yielding a positive result. In these cases it is less sensitive than
generally recognised in sCJD164. Young cases tend to have a longer duration and as
CSF 14-3-3 is a marker of neuronal loss it is more likely to be negative if the neuronal
loss is more protracted. The cerebral MRI has a comparable sensitivity in this
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context, at 56% (n=9), to that seen in sCJD as a whole127 but the EEG, being positive in
only 1.3% (n=31) was less sensitive.
It is likely that problems with case ascertainment are, on the whole, less significant in
the young compared with the old. The exceedingly high profile of vCJD as a
dementia predominantly of the young is likely to have raised awareness of CJD
generally in young people with dementia. People dying under the age of 50 are more
likely to have an autopsy than older people and a couple of "look back" studies
(primarily designed to detect any missed cases of vCJD) have failed to demonstrate
under ascertainment of CJD in the young26'27. Increases in case numbers have been
largely in the over 65 age group since prospective surveillance began in the UK195.
This is thought to reflect improved ascertainment in the elderly but nonetheless
fewer cases are observed in those over 70 years of age (see Figure 1.2) than between
65 and 69 years of age. This may be due to a true decrease in the disease in the very
old or alternatively a failure to detect disease in this age group. It has been
demonstrated in this study that the majority of those under fifty with pathologically
proven sCJD are both suspected in life and referred to the NCJDSU prior to death
(albeit after a longer period of time than that observed in Core sCJD). Of the two
young cases that were not suspected in life as having sCJD both had a duration of
illness of greater than three years which may have contributed more than the young
age to the fact that diagnosis was missed in life. In view of the association with long
duration it cannot be assumed however that all young onset cases will be recognised,
since those with a long duration are possibly the most difficult to detect.
Long duration cases.
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This group includes some of the most unusual and most difficult to diagnose
sCJD cases. This is reflected in the fact that this group has the highest proportion
of autopsy-only diagnoses than any of the other Atypical subgroups or Core
sCJD. Even those neurologists who are most experienced in recognising CJD may
fail to make a diagnosis in such cases. If surveillance is to effectively identify
unusual cases then unusual referrals should be followed up. Surveillance
neurologists should not adhere to too rigid a view of what a case of sCJD consists
of. This is likely to mean that more non-cases may be assessed but this is the only
way to learn more about the spectrum of disease in the most unusual cases.
Personality and behavioural change along with depression are significantly more
common at onset in long duration cases than in a comparison group of Core sCJD
cases. This is important to highlight as these features are generally more associated
with the onset of frontotemporal dementia212 or Alzheimer's disease213. Indeed, the
most important differential diagnosis in the long duration cases is Alzheimer's
disease.
One of the difficulties in making an assessment of disease progression in long cases is
the lack of good quality follow up data. If a patient is seen in life by a NCJDSU
doctor then information is only reliably available up until that point and may not be
provided for the remainder of the disease duration. However, from a review of the
available clinical data in the NCJDSU archive it was possible to ascertain whether
individual long duration cases were truly slowly progressive or whether patients
were being sustained for a long period in a nursed and fed, akinetic and mute state.
In the majority, disease progression was generally much slower than that typically
witnessed in shorter duration cases (with only two of the 28 patients losing the
ability to walk within one year). This is in keeping with the findings of the largest
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published cases series of 33 cases65 with an illness duration of two years or more*. In
the study by Brown et al only three out of 15 patients deteriorated rapidly over a
period of several months and then were sustained in a physically dependent state.
The remainder displayed a more slowly progressive course. The longest period that
any patient in the current study was maintained in a bed bound, fully dependent
state was 50months. This individual was highly unusual in many respects and was
the youngest patients known to the NCJDSU with sCJD".
An important differential in the eleven long duration cases without genetic analysis
is that of genetic CJD, as this is often associated with amore protracted disease
course. None of these patients however had a family history of a CJD-like illness but
it is acknowledged that this is far from conclusive evidence of a sporadic rather than
genetic form of the disease.
A particular difficulty with long duration cases is that, according to current clinical
criteria, none of the cases studied here meet the definition for a case of sCJD. Cases
with a duration of illness greater than two years are automatically excluded unless
they have a positive EEG (Table 1.8). If the case definition were expanded to include
those with a long duration of illness (regardless of the EEG result) a likely
consequence would be a decreased specificity of the case definition criteria.
Alzheimer's disease and other neurodegenerative conditions may also meet the
definition for a Possible case if this occurred.
*
This study included ten familial cases.
"
The neuropathology on this teenager was reviewed following the emergence ofvCJD and found to be
negative for the features associated with this disease.
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Despite the Atypical phenotype, over 60% of long duration cases were referred to the
NCJDSU in life. One of the difficulties inmaking a diagnosis in these cases is that the
investigations traditionally relied on to aid clinical diagnosis in sCJD are often less
sensitive. This was a particular problem with the EEG where it was uncharacteristic
in all 22 of those tested. A low sensitivity of the EEG has been observed before in
long duration cases65. Several factors, including the degree to which sCJD is
suspected, may influence this. For example, in a short duration, clinically typical case
a clinician may expect to see a positive EEG and arrange for repeat tracings to be
taken at time intervals until this appearance is seen. In long duration cases the
diagnosis may be considered unlikely because of the unusual phenotype and
therefore any efforts to elicit repeat recordings may be considered futile. It may also
follow that if a single EEG is performed in a long duration case it is likely to be taken
at a fairly early stage of the illness when a patient is under investigation. In this study
14/28 (50%) of long duration cases were clearly documented as being mobile at the
time of the final EEG and none of the cases had an EEG in the final month of the
illness. Amongst the Atypical cases in this study a positive EEG correlated with an
older age at onset and shorter illness duration. Early EEGs are less sensitive at
detecting the characteristic appearance of sCJD142;145;214 and in our study and others215
there is a correlation with physical dependence and a positive EEG. In other work an
association between shortened survival125 and periodic sharp wave complexes
(PSWCs) on the EEG has been found. All clinically Atypical cases, of any category,
with a positive EEG (who had genetic testing) had an MM genotype at codon 129 and
this supports previous observations87.
The rare combination of Alzheimer's pathology with sCJD122;123 was not an
explanation for the long duration in any of these cases (neuropathology reports were
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reviewed individually) and a complete explanation for the protracted nature of their
illness remains unknown.
Pure visual onset cases
This study has highlighted that judging cases to be Atypical or not by certain features
at presentation may not necessarily identify clinically unusual cases. Three groups
were defined in this way: those with a pure visual onset, those with a cerebellar
syndrome at onset and those with a delay in the onset of a cognitive decline
(associated with another focal onset).
In previous studies patients defined as "Heidenhain" cases have represented up
to twenty percent of sCJD cases82 but definitions have varied from isolated visual
symptoms at onset216 to cases with a mixed presentation of visual and other
symptoms82. Heidenhain's original three cases did not present exclusively with
visual symptoms, in fact one of the cases did not have a visual disturbance at
all72. This study sought to clarify a practically useful definition for "Heidenhain
cases" by focussing on those presenting with visual symptoms in isolation. It was
thought that cases presenting in this way may pose particular early diagnostic
problems and/or raise specific public health issues relating to eye surgery60-217 and
therefore provide a substantial reason for identifying them as a subgroup. Very
early recognition of visual onset cases probably rests with ophthalmologists as
the majority were referred to this speciality initially. However, when pure visual
onset cases were examined, apart from the early part of the illness, they generally
exhibited a typical disease course and were diagnosed relatively early on
compared with Core sCJD cases. The duration of illness was shorter than that
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seen in Core sCJD and the rapidity of decline was often striking. It could be said
that these cases were in some respects the most "typical" of the sCJD subgroups
studied. Notification to the NCJDSU was prompt and overall diagnosis was
rarely delayed beyond two months. The potential remains for needless
intervention in the form of eye surgery218 if the disease is unrecognised in the
early stages and this occurred in two of these cases. As PrP50 has been detected in
the eye219 any intervention involving ocular tissue may pose a risk for onward
transmission of the agent.
The visual onset group identified in this study exhibited less cerebellar or
extrapyramidal signs than a comparison group of Core sCJD cases. This may
reflect the very short duration of illness seen in most visual onset cases where
clinical features are engulfed in a rapid decline with a loss of the cooperation
often required to elicit cerebellar or extrapyramidal features.
It is important to emphasise that in the current study pure visual onset cases
were identified without prior knowledge of genotype (i.e. cases were identified by
a review of the clinical history only). This eliminated selection bias to prove or
disprove any interaction between genotype and phenotype and the subsequent
associations shall be discussed below.
Based on the findings in this study there is little clinical basis upon which to
regard these cases as representing a "variant" of sCJD apart from the presenting
symptom (which does not appear to be a barrier to accurate diagnosis). The term
"Heidenhain variant" may also be misleading in view of the emergence of vCJD.
In many respects these patients are clinically typical for sCJD and, although
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cognitive decline may be delayed at first, visual symptoms appear to be a marker
of a particularly rapid form of the disease.
Those with a cerebellar syndrome at onset
Relatively isolated cerebellar features at onset are well recognised and in that
sense not likely to cause prolonged diagnostic difficulties in those experienced in
diagnosing CJD. However, in the early stages of the disease the differential
diagnosis may be wide and sCJD is often not considered until a dementia
supervenes. A paraneoplastic cerebellar syndrome is a relatively important
differential diagnosis especially as it may be accompanied by a sensory
peripheral neuropathy and sensory features were relatively commonly observed
in this group.
Amongst those presenting with an isolated or relatively isolated cerebellar syndrome
(without an initial cognitive decline) statistically significant association with sensory
symptoms was found (in three cases they were recorded in the very early stages). In
two of Brownell and Oppenheimer's four original cases (that first drew attention to a
cerebellar syndrome at presentation in sCJD) sensory features were prominent. Cases
with a virtually isolated cerebellar onset often exhibit a striking delay in cognitive
decline. In this study, delays in the emergence of a cognitive decline were observed
as much as six months after onset. The increased reported incidence of both visual
and sensory symptoms in this group may in part reflect preserved cognition (i.e. the
retained ability to recognise and complain of an unusual experience).
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An important differential diagnosis in this group is that of genetic prion disease (eg
GSS) which may also present with a cerebellar syndrome and this was not excluded
with genetic analysis in ten cases. None however, had a family history of CJD.
More men (n=17) than women (n=8) were observed as presenting with virtually
isolated cerebellar features. This difference was not statistically significant. There was
a significant difference in the ages observed in the pure cerebellar onset group
compared with Core sCJD (the pure cerebellar cases were younger). This correlates
with the observation that the distribution of codon 129 genotype was significantly
different in this group (more VV, more MV and lessMM). W cases have been noted
previously to be associated with a younger age at onset87;2u. Once cognitive decline
was noted these cases followed a fairly typical clinical course for sCJD.
Investigations including CSF 14-3-3 and MRI were useful in this context. The MRI
displayed a sensitivity of 80% (eight out of ten patients had a positive scan) and the
CSF 14-3-3 was positive in 83% (ten out of 12 patients). The EEG was positive in only
12% (three of the 25 patients tested). This may relate in part to EEG timing as ten of
the 25 patients (40%) were still walking, albeit unsteadily, at the time of the last EEG
recording. All three in whom the EEG was positive were bed bound with myoclonus
at the time of the recording, which correlates with the previously discussed finding
that the EEG is more useful in advanced disease 215.
Amongst the cerebellar onset group a relatively high number of cases were not
referred to the NCDJSU in life (32%). It is worth highlighting the need to ensure
ongoing education and debate amongst neurologists about different presentations in
sCJD if surveillance is to retain or indeed increase its' accuracy. Once more the need
to encourage referral of unusual cases should be emphasised.
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Other focal features at onset in sCJD
Those presenting with another focal symptom (i.e. not visual or cerebellar) where
a global cognitive decline is delayed represent an interesting and heterogeneous
group. This study has highlighted less common presenting symptoms that have
the potential to be misleading if they do not occur in the context of a global
cognitive decline. One of the difficulties that arose when selecting patients to be
included in this group related to the accuracy of the recorded information in
determining whether or not early cognitive decline was present. Since 1997, each
time a NCJDSU doctor assesses a patient they are asked to record the date of
onset of a dementia. If there is a discrepancy of more than one month between
the date recorded as symptom onset and the date recorded as dementia onset
(and if this was backed up by the written clinical history) then a patient was
regarded as having had a delayed onset of cognitive decline. Prior to 1997 a
detailed clinical history was obtained and patients were included in this group if
it was clearly stated that they were "cognitively normal", "not demented" or
"mentally intact" at least one month after symptom onset. These differences in
recording may partially explain why more patients in the focal onset group had a
symptom onset after 1997 as they were often easier to identify. A criticism of this
aspect of the study is that unless a patient has undergone detailed
neuropsychological assessment it is virtually impossible to exclude any cognitive
impairment. Also, early features of a cognitive impairment may include
psychiatric features in isolation such as depression or anxiety. In defence of the
method used here it should be stated that it is largely a pragmatic assessment of
how clinicians view their patients. In reality, assessments of the presence or
absence of cognitive decline are often made by speaking with close relatives and
conducting simple bedside tests. It is accepted that it was virtually impossible to
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exclude subtle cognitive impairment in those presenting with focal features.
Patients were included in this atypical subgroup if there was clear documented
evidence that clinicians, family and the NCJDSU doctor did not perceive them as being
cognitively impaired.
The most common focal symptoms at onset in this group are sensory. Eight of the
twelve with sensory features at onset had unilateral sensory symptoms (e.g.
numbness in left side of face, left upper and/or left lower limb). This is likely to
represent a central nervous system, rather than peripheral nervous system, pattern of
sensory disturbance. In three cases the sensory symptoms were bilateral (tingling
feet/burning feet/numb hands) but in the one of these who underwent
electrophysiological studies no evidence of a peripheral neuropathy was detected.
Since the emergence of vCJD, sensory symptoms may be more likely to be recognised
in CJD as a whole. However, in terms of those who present with sensory features the
numbers have remained fairly constant both before and after 1996 (implying that
these are features that are volunteered by those giving the history and do not have to
be specifically asked for). In vCJD it has been postulated that the sensory features at
onset may represent a thalamic syndrome (mirrored in the pulvinar hyperintensity
seen on cerebral MRI). There was no such pulvinar sign amongst these patients
whose scans we were able to review. There were no reports from local
neuroradiologists of the pulvinar sign being present in the MRI scans not reviewed at
the NCJDSU.
Involuntary movements, without an early global cognitive decline, were uncommon
being seen only in six patients.
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Possibly the most unusual cases in this group are three patients who developed a
flaccid quadraparesis. In one case fasciculations were noted and tendon reflexes,
though maintained, were diminished. Despite accompanying sensory features the
working diagnosis was of motor neuron disease. The second case had an illness
characterised by extreme lethargy, depression and unsteadiness followed by a
severe, flaccid weakness of the upper and lower limbs. This was associated with
areflexia but fasciculations were not observed. Accompanying neurophysiology
revealed a severe axonal peripheral neuropathy. The third case was characterised by
early sensory symptoms followed by a progressive weakness of all four limbs.
Tendon reflexes were maintained, being initially noted as brisk. Peripheral
neurophysiology was not performed. Although lower motor neuron signs are well
recognised in sCJD115 the degree of weakness witnessed in these three cases is
remarkable and caused considerable diagnostic confusion (two were diagnosed at
autopsy and one after a brain biopsy). Unfortunately as the peripheral nervous
system was not examined at autopsy in any of the cases further elucidation of the
pathological processes was not possible but these cases raise questions as to the
effects of disease on the central and peripheral nervous system. Why such unusual
cases would occur remains poorly understood and highlights the importance of
neuropathological examination in detecting cases that are so far removed from the
"typical" disease phenotype.
Although there are problems in considering cases as Atypical on the basis of
presenting features alone, in terms of enhancing early diagnosis this may be useful.
Raising awareness of certain patterns of presentation, including those that are rare,
may aid early recognition of cases that previously have eluded diagnosis until a
rapidly progressive dementia ensued. In some instances, despite the presence of a
dementia, an unusual onset may preclude the diagnosis being made. A description of
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the spectrum of presentation may allow for sCJD to be recognised where previously
it may have been discounted with "sporadic CJD never presents like this". Early
diagnosis is important in terms of provision of care and appropriate counselling for
families as well as enabling relevant public health measures to be implicated. In the
past, failure to recognise more unusual phenotypes at presentation has led to the
reuse of potentially infected surgical instruments.
Evidence has accumulated to demonstrate that different codon 129
polymorphisms affect phenotypeS7;220;221 and this research supports some of the
findings by identifying patients on the basis of phenotype whilst blinded to
genotype. The effect of PrP30 isotype may act independently of codon 129
genotype (e.g. an association with type Ha prion protein and prolonged
survival15). The potential role of geographical and/or environmental factors in
determining phenotype should be explored. Previous studies have alluded to
small geographical clusters of sQD222 224 but it is yet unknown if there is an
association between clinical phenotype and geographical distribution. An
interesting study would be to assess the frequency and nature of Atypical sCJD
across Europe (i.e. in the EUROCJD and NEUROCJD collaborative groups). If
this were to be undertaken however it would be imperative to standardise
definitions and methods of collecting and interpreting data.
The codon 129 genotype in Atypical cases
The association with young onset cases and a particular genotype at codon 129 and
glycotype (where known) is not clear cut amongst our patients. Parchi et al found
that those with a VV2 or MV2 genotype/glycotype were likely to be younger87. In the
young cases studied here the most common genotype was MM. Three young cases
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were MM1 (a genotype/glycotype combination that Parchi found to be associated
with an older age at onset).
In terms of the genotype in the long duration cases studied here, data were
incomplete (11 not having genetic analysis performed) but there was a slight excess
ofMV cases, a finding that has been observed before in those with a longer disease
duration87. There were not any MM1 or VV2 cases in this group (which would fit
with the hypothesis of these genotype/glycotype combinations being associated with
short duration). It should be pointed out that glycotype data was not available on
two MM cases and three VV cases.
All tested visual onset cases had an MM genotype, with a type 1 glycotype where
known. MM1 sCJD is associated with typical clinical features87. In this study pure
visual onset cases have been labelled as Atypical but it has become clear that they
soon evolve into a generally typical sCJD phenotype and it is the onset of disease
only that is unusual.
There was a slight excess of patients with the VV genotype in the pure cerebellar
onset group (predominantly VV2 in keeping with the association that Parchi
described between this group and an ataxic onset87). Patients were identified on the
basis of clinical features alone whilst blinded to genotype at the time of selection. In
contrast to Parchi's work we did find a W1 case presenting in this way (he found
ataxia to be "completely lacking" in this subgroup87). The codon 129 genotype was
known in only five of the ten presenting with sensory symptoms at onset. In four
cases it was MM, in oneW.
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The MRI in Atypical cases
The finding of high signal in the basal ganglia was not significantly different between
Atypical sCJD and cases without Atypical features. In addition correlations between
specific clinical features and basal ganglia high signal were not detected. For
example, those with documented extrapyramidal features were not more likely to
display basal ganglia abnormalities. It remains unclear why some patients display
diagnostically useful features on cerebralMRI whilst others do not. In some
previously studied patients serial MR brain scans showed an increase in
hyperintense signal in the basal ganglia over weeks to months127, whereas in other
publications no increase in hyperintense signals were noted over time225;226.
The cerebral MRI was positive in four out of six long duration cases where the scans
were available for review and, although numbers are very small, it may indicate that
this is a useful diagnostic test (especially as the EEG and CSF 14-3-3 lack sensitivity in
this context). More work is needed to clarify this with larger numbers.
Sporadic CJD as a differential diagnosis of vCJD
Despite the distinct phenotype that is associated with vCJD, on occasion patients
with sCJD have been thought to have vCJD170;227. Young age at onset appears to
influence the perceived likelihood of vCJD as oppose to sCJD. This study has
demonstrated that young cases of sCJD manifest more psychiatric symptoms than a
comparison group of Core sCJD cases. Other features such as ataxia, myoclonus or
psychiatric features later into the illness are common to both diseases and unlikely to
favour vCJD. Known patients with vCJD have fairly uniform pattern of clinical
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presentation and progression 25;37 which is unlike the phenotypic variation observed
in sCJD.
Sensory features are common in vCJD and are also well-documented in sCJD. In
previous studies the incidence was between seven and 16 % at some point in sCJD
64;67;228 Qur study found sensory features to be present at between 10% (Core sQD)
and 70% (Focal onset sCJD). It is possible that since the advent of vCJD sensory
features are more commonly sought after and recognised in sCJD, although for those
with sensory features at onset an equal number were recorded before and after 1996.
Whereas in vCJD sensory symptoms possibly represent a thalamic pain syndrome
(reflected in the hyperintensity seen in the thalamus as the pulvinar sign) 36 in these
sensory onset cases no such thalamic abnormalities are detected on MR imaging.
Brain MRI findings early in sCJD generally point to a more cortical involvement98138,
rather than the basal ganglia abnormalities seen in vCJD.
Underpinning the clinical diagnosis of CJD are internationally agreed case
definitions. A diagnosis of Probable sCJD has a positive predictive value of 97%145
whereas a diagnosis of Probable vQD has not yet been disproved at autopsy
(personal communication, James Ironside). No cases of sCJD to date have met the
clinical criteria for a diagnosis of Probable vCJD. The high specificity of the
classification of Probable vCJD relates largely to the pulvinar sign on brainMR
imaging which is a sensitive and specific marker of vCJD38. Case reports are
emerging of the potential for confusion when interpreting MR scans in this context
and there is a need to use the clear definition of the exact nature of the abnormality229"
231. Periodic sharp wave complexes on the EEG have not been reported in vCJD and
their presence should help to distinguish between the two diseases.
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Cases referred after autopsy: issues in underreporting
These cases are important because they highlight areas where clinical surveillance of
CJD fails. As autopsy rates in the UK continue to decline it is important that every
effort is made to enhance diagnosis and referral of cases in life. Underreporting may
adversely affect public health efforts by distorting trends observed by incidence of
disease, risk estimates for disease acquisition and the geographical distribution of
cases.
Surveillance in the elderly: cases referred after autopsy
This study has demonstrated that cases referred after autopsy are older than those
referred in life. In other words, age influences whether or not patients with sCJD are
detected and referred to the NCJDSU whilst they are alive. It is known that autopsies
are carried out infrequently in the elderly and this raises concerns that cases are
being missed i.e. if the autopsy is not done the case will not come to light. The
decline in numbers of sCJD seen in the elderly (Figure 1.3) cannot be assumed to be
due to a true decrease in case numbers but may reflect underascertainment.
Cases where the diagnosis was not suspected in life
By examining these cases it should be possible to highlight features that cause
particular diagnostic difficulties and areas where clinical surveillance may be
improved upon. Several possible explanations why there is a failure to diagnose
sCJD in life have emerged from this study and include:
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The clinician does not recognise the phenotype of the disease because they are
unfamiliar with sCJD and how it manifests
The clinician (who may be familiar with "typical" sCJD) does not recognise the
disease phenotype because it is unusual and does not fit in with their perception of
what constitutes a case of sCJD
The patient has pre-existing medical problems which cause confusion and to which
the illness representing sCJD is attributed
It is not possible to gain an accurate history of the disease course
Investigations relied upon to aid the diagnosis of sQD are negative
For the first two scenarios it should be possible to increase diagnostic accuracy by
increased education amongst relevant clinicians regarding the nature of the disease.
Unfamiliarity with sCJD.
If it is assumed that a rapidly progressive dementia with death by six months should
at least raise the possibility of the diagnosis in a clinician familiar with the phenotype
in sCJD then a lack of experience may have played a part in 12 cases (2.5% of total
sCJD). In four cases a neurologist had assessed the patient. This may of course have
related to factors other than a lack of familiarity with the condition (for example,
pressures of time when asked to give a second opinion, a lack of available
information regarding disease onset and course).
Maintaining a high level of awareness of the features associated with a condition is
essential for effective disease surveillance. It is difficult to imagine how CJD could
have achieved a higher profile amongst the medical profession than that experienced
as a result of the emergence of vCJD in 1996. Further analysis of the more typical
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missed cases indicates that six of them were unwell in the period following the
emergence of vCJD (1996-2002) and six died prior to 1996. Looking at unsuspected
sCJD cases as a whole it is interesting that the highest number were recorded in 1998
when general interest surrounding QD was probably at its height. More cases were
likely to have been detected because of a peak in the post-mortem examination rate
amongst referrals to the NCJDSU at just over 80%. This suggests that in other years
cases were missed because of lower autopsy rates. It is perhaps surprising that in
1997, shortly after the emergence of vCJD, six suspected cases of sCJD were not
referred to the NCJDSU. One reason for this may be that the perceived focus was so
strongly on detecting vCJD that the importance of referring sCJD cases was
overlooked. Currently autopsy rates for all referrals to the NCJDSU stand at about
65% (as part of a declining trend). This decline forms part of a decrease nationwide in
all autopsies and is likely to mean that cases that would previously have been
diagnosed on autopsy only will be missed.
There are a similar number of Atypical cases amongst those referred after autopsy
and those referred before autopsy. Less than forty per cent of clinically unsuspected
cases exhibited Atypical features (according to the definition used in this study).
There were no cases with a pure visual onset in the unsuspected group reinforcing
the idea that these cases do not cause a great deal of diagnostic confusion except in
the initial phase. The most frequently observed Atypical feature associated with
failing to suspect sCJD was a long duration of illness. It is important that clinicians
are aware that, although extremely rare, sCJD may cause a dementia lasting for
greater than two years. Features which may point to a diagnosis of sCJD despite the
long duration could include a rapid terminal phase, the presence of myoclonus
and/or supportive investigations (especially CSF 14-3-3 or basal ganglia high signal
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on brain MRI). The association highlighted in this study between long duration and
young age should alert clinicians to the possibility of sCJD in younger patients.
Pre-existing medical problems may cause confusion.
Amongst cases only referred after autopsy three clear examples of confusion
associated with pre-existing medical problems emerged. The first related to a prior
diagnosis of terminal cancer, the second to the coexistence of Alzheimer' disease and
the third involved a patient diagnosed with "ischaemic diabetes mellitus-related
cerebellar degeneration". It is perhaps surprising, especially in the first two cases,
that an autopsy was carried out at all and it is unknown how many other cases are
misdiagnosed in this manner without autopsy.
Negative investigations in unsuspected cases.
Of the 26 patients who were not suspected of having CJD whilst alive, 11 (42%) had
an EEG recording. None of these patients had an EEG recording that would have
been regarded as typical/positive. None of these unsuspected cases had CSF 14-3-3
examination. Referral for CSF 14-3-3 implies that the diagnosis of CJD is suspected.
Findings on brain MRI are poorly documented in these cases.
Cases suspected but unreferred in life
Unreferred cases are an inevitability of any surveillance system but efforts
should be made to encourage maximum referral. Of the Atypical cases in those
referred after autopsy (n=21), 12 (57 %) were suspected of having CJD whilst
alive. This suggests that in a suspected case Atypical features may deter referral
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to the NCJDSU. Clinicians may only feel happy to refer a case if they are fairly
certain of the diagnosis and Atypical features may diminish this. It is important
that clinicians appreciate that there is, at times, a diverse phenotypic spectrum in
sCJD.
It is often difficult to be sure from the medical notes exactly why a referral was not
made, as details regarding this are often not recorded. In previous studies of other
disease surveillance, common reasons for non-referral included not knowing how to
report, concerns about confidentiality and a perception that too many diseases
encountered in clinical practice required reporting191. An assumption that someone
else would have reported the patient with suspected sCJD was a factor in some cases
in this study (for example the neurologist assuming the medical team would make
the referral and vice versa).
It is unlikely that any neurologist in the UK has not heard of the NCJDSU but not
every patient with CJD comes into contact with a neurologist. Yearly reminders are
circulated not only to all neurologists but also to neurophysiologists and
neuropathologists. Of those cases not seen by a neurologist (where perhaps the
awareness of the NCJDSU and the criteria for referral are less clear) general
physicians and psychiatrists were most likely to have been the only specialists to
have made an assessment of the patients (alone assessing 13 and 7 of the total
number of 91 unreferred cases respectively). The presence of these patients indicates
that there may have been other similar cases that would not have come to autopsy
(as hospital autopsies are in decline). With vCJD apparently on the decline, interest in
sCJD may also wane and there may be less interest in notifying cases to the NCJDSU.
Education is important as it alerts clinicians to the clinical phenotype and the
appropriate procedures. Methods of increasing awareness amongst these clinicians
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need to be balanced with the time and effort required to enhance referral of a
potentially small number of cases. To include all general physicians and psychiatrists
on the yearly reminder circulation list is logistically a demanding process. There are
other ways of "advertising" the NCJDSU, which may include publications in the
scientific and medical press, presentations at medical conferences and the internet
(see www.cjd.ed.ac.uk).
Possible sCJD: are there ways of improving diagnostic certainty
in this group?
The reason why a case remains classified with the uncertain label of Possible sCJD is
because of a lack of supportive investigations (a characteristic EEG or a positive
CSF14-3-3), a failure to make an alternative diagnosis and the absence of an autopsy.
Assessing the cases classified as Possible has enabled some of the shortfalls of the
diagnostic process to be examined. Every process of this nature should include
feedback into the original system to suggest methods of improvement and a re-
evaluation after a period of time has elapsed (i.e. completion of the audit process).
Shortfalls in the use of diagnostic tests
CSF 14-3-3 has been very useful in enabling many cases to be classified as Probable
sCJD in whom the EEG was not typical. When employed in the correct clinical
context 14-3-3 shows a high sensitivity and specificity for sCJD161;232. Over half of the
patients finally classified as Possible were referred to the NCJDSU before the advent
of CSF 14-3-3. In ten cases referred after the development of the test however, it was
overlooked as an aid to diagnosis. The advent of CSF 14-3-3 test, however, does not
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correlate with a decrease in the number of patients classified as Possible per year or
the proportion of total referrals classed as Possible. Between two and 13 cases a year
have been finally classified as Possible sCJD throughout the study period. Overall
referral numbers have increased whereas autopsy rates have decreased by 20 per
cent over the past seven years (see Figure 3.23) leading to less Definite cases. There is
a trend for the proportion of cases in the Probable sCJD group to have increased and
this may reflect both increased certainty in diagnosis (Possible cases becoming
Probable) provided by CSF 14-3-3 and the decreased number of autopsies carried out
(less Definite cases). The lack of decrease in the number of Possible cases may reflect
an increased tendency to refer cases where the diagnosis is uncertain. In addition the
decline in autopsy rates main mean that more cases are left as Possible only. Only six
of the 59 Possible cases had CSF 14-3-3 performed. This test could be used more
frequently in the future to enhance diagnostic accuracy.
The EEG may have to be repeated on a number of occasions for a characteristic
appearance to develop and it is clear that, in the majority of patients studied here,
multiple EEGs were not recorded. Other factors are also known to increase the
sensitivity of the EEG including later timing of the recording215, older age and a MM
codon 129 genotype 87;233. Possible cases in this study have a mean age of 73 years
(older than that typically seen in sCJD) and a mean duration of illness of five months.
Genotype data was only known in a small minority making it difficult to
meaningfully comment on this amongst these cases. Forty patients (68%) classified
finally as Possible sCJD cases had an EEG recording performed in the second half of
the illness but less than a quarter in the final month. Encouraging an appropriate use
of the EEG (repeatedly and at a late stage in the illness) is important if it is to
continue to be regarded as a useful diagnostic test.
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Underreporting amongst Possible cases
In just under one half of Possible cases the NCJDSU was not notified about the
patient until after they had died. If a suspected case is notified to the NQDSU in life
then advice can be given about investigating appropriately (e.g. send CSF for 14-3-3,
repeat EEG recordings). If a visit is made to see the patient by a NCJDSU doctor then
information regarding the role of the autopsy in diagnosis can be given.
Approximately 60 per cent of Probable or Definite sCJD cases were assessed by a
NCJDSU doctor over the last six years compared with 48 per cent of cases with a final
classification of Possible (NQDSU, unpublished data). This may not just reflect the
direct involvement of the NCJDSU in improving diagnostic certainty but also the
experience of the referring clinicians (i.e. referral is more likely to occur in clinicians
familiar with procedures and therefore more likely to investigate appropriately
anyway). In addition, clinicians may be less likely to refer patients if they are not
confident of the diagnosis and they may not appreciate the need to refer uncertain
cases. It is important that the referral of cases where there is diagnostic doubt is
encouraged.
Re-evaluating aspects of the diagnostic criteria
It has been suggested that there may be a role in the case definition of sCJD for the
appearances of high signal in the caudate head and putamen bilaterally seen in
between 50-60% on the cerebral MRI scan. One of the arguments against this is that
these appearances may be seen in other conditions* and therefore may compromise
specificity. Unfortunately only a small number of MRI scans (15%) were available for
*
Wilson's disease, hypoxic encephalopathy, carbon monoxide poisoning, hepatic encephalopathy.
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review from the Possible cases. Of these, three (33%) showed the characteristic high
signal change in the caudate head and putamen. It would be crucial to view larger
number ofMRI scans on such patients in the future before a decision could be made
regarding the inclusion of this extra factor in diagnostic criteria. Retrospectively
changing the criteria to incorporate the MRI scan as a factor that could define a
Probable case would only have resulted in a further three cases being classified as
Probable on the basis of currently available information.
Another point to consider is a purely clinical one and has arisen largely from the
observation amongst the non-CJD cases that none had a duration of illness of less
than four months. In the Possible group 27 per cent of the cases had a disease
duration of three months or less associated with myoclonus. The findings in this
study indicate that this may be an area for further consideration possibly by
reviewing Europe wide cases to see if the same level of specificity for sCJD occurs
with these very short duration dementias elsewhere. Clearly this would only enable
reclassification of cases after death if this factor were considered specific enough to
enable a classification of Probable CJD to be made.
Cases that were thought to have sCJD but had an alternative
diagnosis proven at autopsy
These cases are interesting because they provide an insight into the extent of the
differential diagnosis when considering a patient with suspected sCJD. An
understanding of this area is particularly important in view of the fact that autopsy
rates are declining, highlighting the need for accuracy in clinical diagnosis wherever
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possible. This study has demonstrated that other neurodegenerative conditions
(especially Alzheimer's disease) and paraneoplastic/neoplastic disorders are most
likely to cause significant diagnostic confusion. Despite this it is noteworthy that of
all the cases referred to the NCJDSU since 1990 only two cases who were classified as
Probable sCJD in life went on to have an alternative diagnosis proven at autopsy
(one had a paraneoplastic disorder with a positive 14-3-3 and the second, who was
diagnosed in 2003 and therefore not included in the results of this study, had an
ischaemic/anoxic encephalopathy and a positive EEG).
A case where an alternative diagnosis was proven at autopsy but
evidence of sCJD was found upon review
An important lesson regarding the interplay of clinical and neuropathological
expertise is learnt with the described case of the 84 year old gentleman who, after an
illness clinically typical of sCJD, had an autopsy which yielded a diagnosis of
Alzheimer's disease. Only in the course of this study (some ten years after the
patients death) was the neuropathology reviewed in light of the overwhelmingly
characteristic clinical picture. The subsequent finding of a dual pathology (of sCJD
and Alzheimer's disease) highlights the need for good communication between
clinicians and neuropathologists as well as emphasising that (especially in the
elderly) more than one pathology may occur121123;234. In previously reported cases
where both sCJD and Alzheimer's disease were found at autopsy clinical features
varied. One report details a slowly progressive illness over five years with a rapid
exacerbation of symptoms in the last three months123 whilst another describes
akinetic mutism two months after the initial symptoms235.
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More advanced neuropathological techniques are now available for detecting PrP80
and it is possible that other similar cases may exist that have been overlooked in the
past. Clearly the detection of such a case many years after death has implications for
the family members and care needs to be taken in communicating such a result back
to unsuspecting relatives. Such cases are likely to be rare however and in this study a
review of other "non-cases" revealed two further cases with an autopsy diagnosis of
Alzheimer's disease and a duration of illness of less than six months. A detailed
neuropathological review in these additional two cases failed to reveal any evidence
of PrPSc. An interesting further study may be to review the neuropathology of other
cases throughout Europe with a short duration of illness referred as suspect sCJD but
given an alternative diagnosis at autopsy.
There are no other cases known to the NCJDSU with a dementing illness lasting three
months or less with a diagnosis other than CJD. This implies that a feature specific to
sCJD, at least in those cases referred to NCJDSU, may be the incredible rapidity of
decline often observed. It is possible, however, that this may be an artefact of the
cases referred to the NCJDSU, i.e that rapidly progressive dementias of other cause
may be recognised and diagnosed by local clinicians without referral to the NCJDSU.
Distinguishing other diseases from sCJD
Has this study brought us any further forward in being able to differentiate other
conditions from sCJD? On the whole in non cases disease duration was considerably
longer than that witnessed in sCJD although on an individual basis there was
overlap between the two groups. In patients referred to the NCJDSU with an illness
duration of less than three months, sCJD is found unanimously at autopsy.
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Undoubtedly at times the presence of myoclonus and a rapidly progressive dementia
may be misleading, pointing towards CJD when the diagnosis is an alternative
condition91. As previously described, the clinical diagnostic criteria are accurate in
terms of filtering out non-QD cases (i.e. a Probable diagnosis carries with it a high
specificity) and therefore it is better that the initial referrals are relatively broad to
decrease the chance of cases being missed. There are no cases in the cohort of non
cases studied here with myoclonus, a rapidly progressive dementia and a typical
EEG.
It is important not to discourage the referral of longer duration cases that are more
likely to have Alzheimer's (AD) or another condition. This work indicates that
among this group there may be unusual cases of sCJD. This study has not identified
features that clearly distinguish long duration sCJD from alternative diagnoses such
as AD. This emphasises the need for an autopsy to be sure of the diagnosis. Clinical
diagnostic accuracy for AD rests at between 62.5% and 100%236;237 and previous
studies have highlighted several factors as potentially alerting a clinician to an
incorrect diagnosis of AD (including focal neurological signs and extrapyramidal
features)238. Cases that were labelled in life as having AD and went onto autopsy
have on occasion had coexistent CJD but there has not been a high prevalence of
undiagnosed sCJD234. Some of the long duration cases in this study had an autopsy
because of features that were unusual (e.g. young age or rapid terminal decline).
There may however be cases where these unusual features do not occur, are labelled
as AD and do not have an autopsy. There has been a decline, since 1996, in the
number of non-cases referred to the NCJDSU who had Alzheimer's disease (AD)
proven at autopsy. This may indicate that some long duration sCJD cases are being
missed as in this study cases have been shown to arise from the premortem cohort of
"suspected AD". It also may mean, however, that there is a greater awareness of
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This study has demonstrated that sporadic Creutzfeldt-Jakob Disease manifests
in clinically distinct ways. By describing cases observed over a twelve year
period it has provided a comprehensive review of the phenotypic spectrum.
Unusual cases may cause problems in diagnosis if rigid ideas regarding disease
presentation and progression are adhered to. It is important that those involved
in the field of CJD surveillance encourage the referral of unusual cases and
continue to be involved in maintaining a high level of awareness regarding the
disease and its different manifestations. Methods to increase the
representativeness of surveillance are important if an understanding of the
patterns of disease is to be complete.
This study has identified circumstances where weaknesses in case detection may
exist. It has highlighted methods of enhancing future diagnostic accuracy by the
appropriate use of diagnostic tests such as the EEG, which should be repeated
late into the illness. Long duration cases may pose particular problems in
diagnosis, both by not exhibiting the rapidity of decline so striking in many cases
of the disease and also because diagnostic tests have low positive yields. It is
important that sCJD is thought of in unusual dementias, and it is hoped that the
NCJDSU is approached readily for advice. For their part, surveillance
neurologists must encourage the referral of unsual cases and keep an openmind
to phenotypic variations, especially in cases with a longer illness duration. This
may increase the rate of autopsy examination in such cases, which may be the
only way to make a positive diagnosis.
Prion diseases are particularly devastating conditions. By active and accurate
surveillance it is hoped that more may be understood regarding pathogenesis
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Appendix 1: Surveillance case definition for Variant CJD
I A Progressive neuropsychiatric disorder
B Duration of illness > 6 months
C Routine investigations do not suggest another diagnosis
D No history of potential iatrogenic exposure
E No evidence of a familial form of CJD
II A Early psychiatric symptoms1
B Persistent painful sensory symptoms2
C Ataxia
D Myoclonus or chorea or dystonia
E Dementia
III A EEG does not show the typcal appearance of sporadic CJD3
(or no EEG performed)
B MRI brain shows blateral symmetrical pulvinar high signal4
IV A Positive tonsil biopsy
DEFINITE IA and neuropathological confirmation of vCJD
PROBABLE I and 4/5 of II and IDA and IIIB
OR
I and IVA
POSSIBLE I and 4/5 of II and IDA
1
depression, anxiety, apathy, withdrawal, delusions
2 this includes both frank pain and/or dysasesthesia
3
generalised triphasic periodic complexes at approximately one per second
4 relative to the signal intensity of other deep grey matter nuclei and cortical grey matter
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Appendix 2: EEG classification used by the NCJDSU
I Normal
II Non specific
Non-specific deterioration in normal background activity
Non-specific excessive slow wave activity
Non-specific excessive fast wave activity
III Suggestive
General deterioration in/loss of normal background
Intermittent bi/tri phasic discharges similar to those seen in classical CJD
records
BUT
a) occurring in bursts of only relatively short duration (<15 seconds)
AND either b) or c) or both
b) not being truly generalised and synchronous
c) without true periodicity
IV Highly Suggestive
Generalised deterioration in /loss of normal background
Intermittent bi/tri phasic discharges similar to those seen in classical CJD
records
Being truly periodic and generalised at times
BUT
Either a) or b)
a) occurring in bursts of only relatively short duration (<15 seconds) and
occupying less than a quarter of the record
b) not being truly generalised and synchronous in all portions of the
record where they occurred
V Typical
General deterioration in/loss of normal background
Truly periodic generalised synchronous bi/tri phasic discharges
Occuring throughout the whole record or at least one quarter of it and in
relatively long segments (15 seconds at a minimum)
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Appendix 3: Patient review and examination forms, pre-
and post-1997
Patient Review and Examination Form (Post-1997)
1. Identification information Id number
1.1 What is the patient's name: First name
Surname
1.2 Name of the patient's consultant:





Patient's hospital record number
1.4 Who is the patient's G.P.? Surname+initial




1.6 Patient's NHS number: old:
new:
1.7 Date of examination (dd/mm/yyyy): / /
1.8 Examination performed by:
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2. Clinical history (continued)
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3. State of patient at admission/first examination by a neurologist
3.1 General appearance:












4. Previous medical history
Complete this section oftheform using the medical notes available. All questions refer to the patient's history
prior to the onset ofthe current illness.
4.1 Does the patient have a record ofprevious
hospital admissions unrelated to the present
illness? (l=yes, 2=no)
{Ifyes), on how many occasions has the
patient been admitted to hospital? (88~not
applicable)
{Ifyes) record the hospital's name, the date(s)
of admission and the reason(s) for the
admission?
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4.2 Has the patient ever had a diagnosis of inflammatory bowel
disease? (l=yes, 2=no)
(Ifyes) record date of first diagnosis (dd/mm/yyyy) / /
4.3 Has the patient ever been diagnosed as diabetic? (l=yes, 2=no)
(Ifyes) record date of first diagnosis (dd/mm/yyyy)
/ /
(Ifyes) has the patient received insulin? (l=yes, 2=no)
(Ifpatient has received insulin) record date of first and last
prescription (dd/mm/yyyy) / / First
/ / Last
4.4 Has the patient ever undergone surgery requiring a general
anaesthetic? (l=yes, 2=no)
(Ifyes) record the date of the surgery, the procedure(s)
performed, and the name of the hospital where the procedure(s)
took place.
4.5 Has the patient ever undergone surgery without general
anaesthetic? (l=yes, 2=no)
(Ifyes) record the date of the surgery, the procedure(s)
performed, and the name of the hospital where the procedure(s)
took place.
4.6 On how many occasions in all has the patient undergone surgery
(with or without general anaesthetic)?
4.7 Has the patient ever received an organ transplant (including
□corneal or bone marrow transplant)? (l=yes, 2=no)
{Ifyes) record the date, organ received and name of hospital.
4.8 Has the patient ever received blood or blood products? (l=yes,
2=no)
{Ifyes) record the date, type ofproduct, name of hospital and
reason.
4.9 Has the patient ever received a treatment involving a course of
injections (excluding any treatments related to the current illness)?
(l=yes, 2=no)
{Ifyes) record the year of the treatment, the medication(s) involved
and the reason.
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4.10 Non-injectable treatments lasting more than 4 weeks: record the start date of the treatment, the





















4.11 Has the subject ever been exposed to one of the medications of bovine
origin withdrawn in 1990? (l=yes, 2=no)
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6. Recording/coding of history and examination
6.1 What were the first symptoms of illness noted by the patient or
their family?
When did these symptoms first occur? (dd/mm/yyyy) / /
6.2 When did the patient first seek medical attention for the illness? / /
(dd/mm/yyyy)
6.3 When was the patient first referred to a neurologist? / /
(dd/mm/yyyy)
/ /
6.4 When was the patient first admitted for the current illness?
(dd/mm/yyyy)
6.5 Since the start ofthe illness, until the current time, has the
patient exhibited the following neurological symptoms/signs:






Coding: l=yes, 2=no, 3=unsure,
9=not able to ascertain. If yes, but





pyramidal signs / /
extrapyramidal signs / /















6.6 Since the start of the illness, until now, has the patient exhibited
the following clinical symptoms/ signs: {ifyes record the date





6.7 Since the start of the illness, has the patient been seen by a
psychiatrist? (l=yes, 2=no)
{Ifyes) record the date of the first consultation (dd/mm/yyyy)
6.8 Since the start ofthe illness until now, has the patient exhibited
the following psychiatric symptoms/signs: {ifyes record the
date ofthefirst appearance ofthe symptom/sign)
clinical depression
social withdrawal









Coding: l=yes, 2=no, 3=unsure,
9=not able to ascertain. If yes, but





Coding: l=yes, 2=no, 3=unsure,
9=not able to ascertain. If yes, but
date unknown record as 09/09/0909
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7. Investigations
7.1 Has the patient undergone an EEG? (1 =yes, 2=no)
(Ifyes), on how many occasions?
(Ifyes), record date ofmost recent EEG (dd/mm/yyyy)
Are EEG records/copies available in the Unit? (l=yes all,
2=yes some, 3=no, 8=not applicable)
Have the EEGs been examined by a Unit staff member? (l=yes
all, 2=yes some, 3=no, 8=not applicable)
7.2 Has the patient recorded an EEG characteristic ofCJD
(generalized triphasic periodic complexes with frequency about
l/s)?(l=yes, confirmed by Unit staff, 2=yes, reported by local
staff, EEG not available for confirmation by Unit staff, 3=no,
8=no EEG performed)
What was the basis for the classification of the EEG?
(l=informal, 2=Oxford criteria, 3=Gottingen criteria,
4="WHO" criteria, 8= no EEG performed)
(Ifyes) record the date on which the first characteristic EEG
was recorded (dd/mm/yyyy)
7.3 Has the patient ever had a CT scan? (l=yes, 2=no)
(Ifyes), on how many occasions?
(Ifyes), record date ofmost recent scan (dd/mm/yyyy)
Are CT scan results available in the Unit (l=yes all, 2=yes
some, 3=no, 8=not applicable)
Have the CT scans been examined by a Unit staffmember?
(l=yes all, 2=yes some, 3=no, 8=not applicable)
7.4 Has the patient ever had an abnormal CT scan? (l=yes,
confirmed by Unit staff, 2=yes, reported by local staff, scan not
available for confirmation by Unit staff, 3=no, 8=no scans
performed)
(Ifyes) record the date on which the first abnormal scan was
performed (dd/mm/yyyy)
(Ifyes) specify what abnormalities have been observed
7.5 Has the patient ever had an MRI scan? (1 =yes, 2=no)
(Ifyes), on how many occasions?
(Ifyes), record date ofmost recent scan (dd/mm/yyyy) / — /
AreMRI scan results available in the Unit (l=yes all, 2=yes
some, 3=no, 8=not applicable)
Have the MRI scans been examined by a Unit staff member?
(l=yes all, 2=yes some, 3=no, 8=not applicable)
7.6 Has the patient ever had an abnormal scan? (l=yes, confirmed by
Unit staff, 2=yes, reported by local staff, scan not available for
confirmation by Unit staff, 3=no, 8=no scans performed)
(Ifyes) record the date on which the first abnormal scan was
performed (dd/mm/yyyy) /
(Ifyes) specify what abnormalities have been observed
7.7 (Ifan abnormalMRI scan has been reported by someone outside




7.8 CSF findings (fill coding boxes with 8s if test results are not
available)














Ig oligoclonal bands in: CSF
blood 1 =positive, 2=negative
Date of second CSF collection (dd/mm/yyyy) 1 =positive, 2=negative
















7.9 Has the patient had any abnormal liver function test results
recorded? (l=yes, 2=no)
(Ifyes) specify abnormality and give date of first abnormal
test:
7.10 Does the patient have any abnormalities on other routine
biochemical/haematological investigations? (l=yes, 2=no)
(Ifyes) give describe the investigation(s) and the abnormalities
7.11 Has the patient undergone a brain biopsy? (l=yes, 2=no)
(Ifyes) what was the result? (l=no evidence of spongiform
change, 2=spongiform change without florid plaques,
3=spongiform change with florid plaques, 4=result not yet
available, 8=no biopsy performed)
Name ofneuropathologist:
7.12 Has the patient undergone a tonsil biopsy? (1 =yes, 2=no)
(Ifyes) what was the result? (l=no evidence ofPrP
immunostaining, 2=equivocal, 3=PrP positive, 4=result not yet
available, 8=no biospy performed)
8. Specimens collected
8.1 Blood: frozen for general use




9.1 On the basis of the available information, what is the
classification of the patient? (1.0=definite CJD, 2.0=probable
CJD, 3.0=possible CJD, 4.1 ^diagnosis unclear, 4.2=CJD
thought unlikely, 4.3=definitely not CJD, 5=GSS)
(Ifpatient is classified as at leastpossible CJD or GSS) which
category of disease is suspected? (S=sporadic CJD, N=nvCJD,
F=familial CJD, I=iatrogenic CJD, G=GSS, 8=not applicable)



































a) Date of death:
Place of death:
Cause of death:
b) Review of clinical course:
c) EEG progression:
d) Abnormalities in other investigations:
e) Post-mortem: Yes/No
Histology
















Classification CJD - Definite
- Probable
- Possible
Other
264
